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ABSTRACT 
 
 Objectives: Ileal pouch anal anastomosis (IPAA), the removal of the colon and 
formation of a reservoir from ileum, is the surgery of choice for ulcerative colitis and 
familial adenomatous polyposis. Yet, 10 to 35% of patients develop pouchitis, an 
inflammation of the pouch mucosa. Microbial imbalances are observed in pouchitis and 
inulin has been suggested as a prebiotic treatment. Our objectives were to determine the 
effect of inulin supplementation on quality of life (QOL), and its practicality and safety 
as a treatment in IPAA patients.  
 Methods: Adults with IPAA (n= 8) consented to a blinded, placebo-controlled 
trial of inulin supplementation. Baseline symptoms were measured for 1 month prior to 
supplementation, followed by a blinded low-dose (5 g of inulin) or placebo 
(maltodextrin) for 2 weeks and a higher-dose (10 g) for 5.5 months. Participants 
recorded any symptoms that they experienced in a diary and QOL was assessed using 
the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at the beginning and end 
of the study. 
 Results: Two participants in the same group developed significant side effects 
on the 10 g supplementation; abdominal discomfort, severe gas, and small amounts of 
blood with defecation were reported. Unblinding determined that these participants were 
taking the active treatment (inulin); therefore, the study was stopped early. No 
differences were observed in SIBDQ scores.  
 Implications & Conclusions: In this pilot study, inulin appeared to be 
ineffective in improving QOL and may have contributed to unpleasant side effects. 
iii 
Future research should explore synbiotic therapy in IPAA, by combining prebiotics and 
probiotics for optimal results.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
 Ileal pouch anal anastomosis (IPAA) is the surgical procedure of choice for the 
management of ulcerative colitis (UC) and familial adenomatous polyposis (FAP) 
(Welters et al., 2002). The IPAA procedure involves removal of the colon and formation 
of a reservoir from 30 to 40 cm of ileum and preserves the anal sphincter to maintain 
anal continence (Blumberg & Beck, 2002). As reviewed by Winkler (2003), the villi of 
the IPAA adapt to become more histologically similar to colonic mucosa. 
While IPAA is a positive experience for many patients, between 10 to 35% will 
develop pouchitis in the first 10 years, with a peak incidence at 18 months after surgery 
(Blumberg & Beck, 2002). Pouchitis involves inflammation of mucosa, characterized by 
abdominal pain, urgency, bloody or mucous diarrhea, fever and/or general malaise 
(Turina et al., 2006). Pouchitis can be either acute or chronic in nature and the quality of 
life of patients is negatively impacted (Winkler, 2003). Quality of life, satisfaction with 
IPAA surgery, subjective health, and energy levels have been found to be significantly 
lower in patients with chronic pouchitis (p<0.01) (Turina, et al., 2006). Conventional 
treatment of pouchitis with antibiotics is not satisfactory for all patients, as relapse is 
common (5-15% with IPAA for UC), a condition known as “refractory or frequent 
recurrent pouchitis” (Mimura et al, 2004).  
The predominant theory of the pathogenesis of pouchitis is a microbial 
imbalance of the pouch (Ohge et al., 2005). Studies of fecal flora from pouches are 
associated with decreased counts of Lactobacillus and Bifidobacterium (Winkler, 2003). 
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Thus, increasing the counts of these bacteria may restore the microbial balance of the 
pouches. Prebiotics are being considered as an alterative treatment for pouchitis, as 
prebiotics are food ingredients that stimulate the growth of Lactobacillus and 
Bifidobacterium in the gut (Cummings & Macfarlane, 2002). Winkler (2003) suggested 
that prebiotics may facilitate recolonizing the pouch with these beneficial bacterial with 
no known harmful effects. A potential prebiotic intervention for pouchitis is inulin 
supplementation to create positive shifts in intestinal flora. Inulin is a prebiotic dietary 
fibre supplement that is fermented into short chain fatty acids and leads to lower 
intestinal pH (Kruse, Kleesen, & Blaut, 1999).  
 One known study has investigated the use of inulin in patients with pouchitis. In 
a three-week cross-over design study, twenty patients with pouchitis received either 
large doses of inulin or placebo (24 g). Fecal samples were analyzed for pH, short chain 
fatty acids, microflora, and bile acids. The researchers concluded that inulin fibre 
supplementation led to decreased inflammation of the pouch mucosa (Welters et al., 
2002). This short-term study by Welters et al. provides evidence for the effect of inulin 
supplementation at the microbial level; however, no studies have addressed the 
effectiveness of long-term inulin supplementation on the reduction of pouchitis and 
pouch problems. In addition, we were unable to find studies of the effect of inulin 
supplementation on the quality of life of individuals who are afflicted by chronic 
pouchitis.  
 
1.2 Purpose 
 This study builds on the short-term inulin supplementation study by Welters et 
al. (2002). The Welters et al. trial was short in duration and therefore did not examine 
3 
the long term practicality of inulin supplementation. The purpose of this study was to 
determine if consuming inulin will decrease pouchitis and pouch problems and improve 
the quality of life of patients with IPAA. Positive results from this study could provide 
evidence for inulin supplementation and may affect the treatment and prevention of 
pouchitis, and ultimately may improve quality of life for patients with IPAA. 
 
1.3 Objectives 
 There are three main objectives of this study: 
 1. To determine if inulin supplementation is a practical and safe nutritional 
 recommendation for patients with chronic pouchitis. 
2. To determine if inulin supplementation affects the incidence of pouchitis and 
problems of fecal frequency in patients with IPAA. 
3. To determine if inulin supplementation affects the quality of life in people 
with IPAA. 
 
1.4 Hypothesis 
 It is hypothesized that the administration of inulin fibre will decrease the 
incidence of pouchitis and problems of fecal frequency and abdominal symptoms in 
patients with IPAA. It is also hypothesized that inulin fibre supplementation will be 
associated with positive quality of life scores in people with IPAA. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Fermentation and the Role of Microbial Competition in Colonic Health  
 Competition for substrates within the microbial community of the intestines has 
been implicated in the maintenance of gastrointestinal health and in the etiology of 
diseases of the colon (Louis, Scott, Duncan, & Flint, 2007).  
 
2.1.1 Carbohydrate Fermentation 
The major products of carbohydrate fermentation are short chain fatty acids 
(SCFAs), carbon dioxide (CO2), methane (CH4), hydrogen gas (H2), and heat (Topping 
et al., 2001).  
SCFAs are monocarboxylic hydrocarbons that contain 1 to 6 carbon atoms (Kles & 
Chang, 2006). As presented in Table 2, the SCFAs produced in the colon are acetate, 
propionate, and butyrate. Acetate is the principal SCFA in the colon; however, butyrate 
is the preferred nutrient for colonic epithelial cells, favored over acetate or propionate, 
and over glucose or glutamine supplied from the blood (McGarr et al., 2005). 
 
Table 2.1 Relative Percent of the SCFAs Produced in the Colon  
(adapted from McGarr et al., 2005) 
SCFA Acetate Propionate Butyrate 
Formula CH3COO- CH3CH2COO- CH3CH2CH2CHOO-
Approximate percent of total 
SCFA produced 
 
70 
 
20 
 
10 
 
 The SCFA butyrate has been studied for its cancer preventing role. Butyrate 
prevents cell differentiation, enhances apoptosis of transformed colonocytes, and 
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decreases the transformation of primary to secondary bile acids (McGarr et al., 2005). 
Several reviews have demonstrated that low concentrations of butyrate increase the risks 
of both colorectal cancer and inflammatory bowel diseases (McGarr et al; Pryde et al., 
2002; Topping et al., 2001). 
 Carbohydrate fermentation also yields gases: CO2, CH4 and H2 (Topping et al., 
2001). Efficient mechanisms for H2 disposal has evolved into three groups of bacteria 
found in the colon: methanogenic archaea (methanogens), sulfate-reducing bacteria 
(SRB), and to a much less extent by acetogenic bacteria (McGarr et al., 2005). Hence, 
the main competition for hydrogen is between the methanogens and SRB. However, 
when an adequate sulfate source is available, SRB quickly outcompete methanogens for 
H2 (McGarr et al., 2005). Competition for H2 may have implications for development of 
colon cancer (McGarr et al., 2005). Methane, produced from the oxidation of H2 by 
methanogens, is absorbed into portal blood and excreted in the breath (Segal, Walker, 
Lord, & Cummings, 1988), whereas SRB produce cytotoxic hydrosulfide anions (H2S), 
which is not excreted in the breath, and has local, detrimental effects on the colon 
(McGarr et al.; Picton, Eggo, & Singh, 2007).  
 Hydrosulfide anions permeate the colonocyte membranes easily and affect cell 
functions (Fiorucci, Distrutti, Cirino, & Wallace, 2006) and prevent the oxidation of 
butyrate, the main nutrient for colonic epithelial cells (Picton et al., 2007). In addition, 
higher than normal levels of H2S have been found in individuals with colon cancer and 
inflammatory bowel disease, and research efforts have attempted to link excess H2S 
exposure and impaired H2S clearance to the pathogenesis of these diseases (Picton et al., 
2007). 
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 Individuals exhibit variation in levels and activity of SRB, ranging from 
undetectable to high (Florin, Neale, Gibson, Christl, & Cummings, 1991; McGarr et al., 
2005). The individual variability of SRB is significantly related to dietary practices 
(McGarr, et al., 2005). Food sources of sulfate include meat, seafood, commercially-
prepared bread, beer, dried nuts, dried fruit, brassica vegetables (such as broccoli and 
cauliflower), and drinking water (Florin et al., 1991). Due to the abundance of sources of 
sulfate in the average diet, an individual could reduce their intake of sulfate-containing 
food, but complete avoidance of sulfate ingestion would be extremely difficult. 
Moreover, avoidance of all dietary sources of sulfate would also be inadvisable, because 
H2S is also interestingly implicated in the prevention of tissue damage and 
inflammation. As reviewed by Fiorucci et al. (2007), studies show that H2S helps to 
prevent cardiovascular disease and some gastrointestinal conditions, such as Aspirin-
induced gastritis.  
 
2.1.2 Protein Fermentation 
 At least 50% of protein fermented in the colon is from dietary protein. Other 
sources of protein fermented in the colon are enzymes, sloughed-off epithelial cells, 
bacterial lysis products, and mucins (Leu et al., 2007). Colonic fermentation of proteins 
results in formation of ammonia, nitrosamides, thiol, phenolic compounds, and branched 
chain fatty acids (Ichikawa & Sakata, 1998; Leu et al., 2007). The products of protein 
fermentation in the colon are believed to be toxic to colonocytes. For instance, ammonia 
has been associated with shortened colon cell life span, altered DNA synthesis in the 
colon, and is thought to promote colon carcinogenesis (Ichikawa & Sakata, 1998).  
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 Carbohydrate fermentation decreases bacterial metabolism of proteins and 
increases bacterial uptake of intermediary metabolites of protein breakdown (Leu et al., 
2007). Thus, carbohydrate fermentation protects the colonic mucosa from the 
detrimental effects of protein metabolism. Supplementation with probiotics and 
prebiotics could also protect from protein fermentation in the colon; as lactic acid 
bacteria primarily ferment carbohydrate, and could outcompete microbiota that ferment 
protein (MacFarlane, MacFarlane, & Cummings, 2006).  
 
2.1.3 Balanced Intestinal Microbiota 
 Healthy (or balanced) intestinal microbiota has been associated with reduced risk 
of colon disease (MacFarlane et al., 2006; Wong et al., 2006). Healthy microbiota 
contains high levels of bacteria from the genera Bifidobacterium and Lactobacillus 
(MacFarlane et al., 2006; Wong et al., 2006). Interestingly, species of the genera 
Lactobacillus and Bifidobacterium are not the most numerous bacteria ordinarily present 
in the colon. Rather, it is the Bacteriodetes and the Firmicutes, which includes Bacilli, 
Clostridia, and Mollictues, that are the most abundant (Louis, et al., 2007; Todar, 2005, 
Duncan et al., 2003). The Bacteriodetes and Clostrida primarily metabolize protein and 
ferment amino acids, resulting in products that are harmful to the colon (MacFarlane et 
al., 2006). In contrast, Lactobacillus and Bifidobacterium are primarily carbohydrate 
fermenting, and yield products that are beneficial to colon health, such as SCFAs 
(MacFarlane et al., 2006). Lactobacillus and Bifidobacterium do not contain any 
pathogens and are associated with colonization resistance to pathogens (Gibson, 
McCartney, & Rastall, 2005). Prebiotic and probiotic supplementation has emerged to 
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increase the representation of Lactobacillus and Bifidobacterium, and selectively 
promote the growth of these healthy colon microbiota (Wong et al., 2006).  
 
2.1.4 Probiotics 
Probiotics are live microorganisms which, when administered in adequate 
amounts, benefit the host (Food and Agriculture Organization of the United Nations and 
World Health Organization [FAO/WHO] Report, 2002). The most commonly used 
bacteria in probiotic supplements are the lactic acid- producing bacteria, including the 
species Lactobacillus and Bifidobacterium (Parvez, Malik, Ah Kang, & Kim, 2006). 
Probiotics compete with other bacteria for nutrients and thus create a colonic 
environment that is less conducive for the growth of potentially pathogenic or protein-
fermenting bacteria (Bongaerts & Severijinen, 2001). 
Marteau, de Vrese, Cellier, and Schrezenmeir (2001) and Santosa, Farnworth, 
and Jones (2006) conducted systemic reviews of the potential health claims for 
probiotics, as related to gastrointestinal health. They observed an overall protective 
effect of probiotics for the prevention and treatment of antibiotic-associated diarrhea, 
with particularly strong evidence for Lactobacillus in treating rotavirus infection-
induced diarrhea. In addition, clinical trials have demonstrated a reduction of irritable 
bowel syndrome symptoms due to probiotic administration. Santosa et al. also note there 
is some evidence from animal studies for the efficacy of probiotics in the treatment of 
inflammatory bowel disease and for cancer prevention; however, they caution that there 
are a limited number of randomized-control trials to draw conclusions about these 
specific health claims.  
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2.1.5 Prebiotics  
 2.1.5.1 Prebiotics Defined 
 Prebiotics are non-digestible food ingredients that beneficially affect the host by 
selectively stimulating the growth and activity of specific bacteria in the colon (Gibson, 
Probert, Van Loo, Rastall, & Roberfroid, 2004). In particular, prebiotics stimulate the 
growth of lactobacilli and bifidobacteria (Cummings & MacFarlane, 2002). Gibson et al. 
and Roberfroid (2007) describe strict criteria for the classification of prebiotics. 
Prebiotics must demonstrate (1) resistance to hydrolysis by mammalian enzymes, to 
gastric acidity, and to gastrointestinal absorption; (2) fermentation by intestinal 
microflora; and (3) selective stimulation of the growth and/or activity of those intestinal 
bacteria that contribute to health and well-being. According to Gibson et al., only three 
food ingredients can be classified as prebiotics based on these criteria: inulin (including 
fructooligosaccharides (FOS) or oligofructose), trans-galactooligosaccharides, and 
lactulose.  
 Roberfroid contradicts the decision regarding the third food ingredient (lactulose) 
by stating, “Presently there only two food ingredients that fulfill this criteria, i.e. inulin 
and trans-galactooligosaccharides (TOS)” (Roberfroid, 2007, p. 831S). This statement is 
not in agreement with a table in this same article which states that lactulose does have 
prebiotic status (Table 4: Summary and conclusion on the prebiotic effect of various 
oligosaccharides, Roberfroid, 2007, p. 853S).Galactoooligosacchardies and lactulose 
appear identical in terms of meeting the criteria; however, in the text of the article 
Roberfroid only remarks on inulin and galactooligosaccharides as prebiotics. 
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Table 2.2: Prebiotic Status of Oligosaccharides  
(Adapted from Prebiotics: The Concept Revisited, Roberfroid, 2007) 
Oligosaccharides Classified as Prebiotics 
Inulin and oligofructose 
Galactooligosaccharides 
Oligosaccharides: Candidates* for Prebiotic Status 
Lactulose 
Isomaltooligosaccharides 
Lactosucrose 
Xylooligosaccharides 
Soybean oligosaccharides 
Glucooligosaccharides 
(*More research is required to determine if the properties of non-digestibility, selectivity 
or fermentation are satisfied) 
 
 MacFarlane, Steed, and MacFarlane (2008) recently been amended the Gibson et 
al. (2004) and Roberfroid (2007) prebiotic definition to: “a prebiotic is a selectively 
fermented ingredient that allows specific changes, both in the composition and ⁄ or 
activity in the gastrointestinal microbiota that confers benefits upon host well-being and 
health.” 
 Kuisma et al. (2003) postulated that lactose may also be a prebiotic, based on the 
negative correlation they observed in aerobes and lactose consumption in IPAA patients 
and a review of early observational studies. However, lactose was not mentioned in the 
Gibson et al. review (2004) or the Roberfroid et al. review (2007). A possible reason for 
the exclusion of lactose in this discussion would be that, in lactose-tolerant adults, 
lactose is absorbed in the small intestine, thus it would not fulfill the first and second 
criteria of prebiotics (resistance to hydrolysis by mammalian enzymes, to gastric acidity, 
and to gastrointestinal absorption and fermentation by intestinal microflora) according to 
Roberfroid et al. and Gibson et al. 
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 The results of prebiotic trials for the treatment and prevention of diseases of the 
colon are promising; yet MacFarlane et al. (2006) criticize the lack of randomized-
control trials to test the clinical effects of prebiotics on irritable bowel syndrome and 
inflammatory bowel disease, and judge the evidence for prebiotics in the prevention of 
diarrhea and colon cancer as weak. 
 Non-starch polysaccharides (dietary fiber), resistant starches, sugar alcohols, and 
lactose become substrates for microbial fermentation when they reach the colon. 
Compared to prebiotics, microbial growth stimulation by these undigested carbohydrates 
is non-specific, and promotes the growth of both pathogenic and beneficial bacteria, 
whereas prebiotics, by definition, specifically stimulate the growth of mainly beneficial 
bacteria (MacFarlane et al., 2006). Ingestion of prebiotics increases the production of 
butyrate (Louis et al., 2007).  
 One might assume that it is the Lactobacilli and the Bifidobacterium that 
predominantly produce butyrate, due to their association with a healthy gut environment, 
and because prebiotics stimulate the production of both these beneficial bacteria and 
butyrate. Yet, it is actually bacteria from Clostridia that are primary butyrate producers 
(Louis et al., 2007). The concept of metabolic cross-feeding is used to explain the 
increase in butyrate that is accompanied by the increase in lactic acid bacteria (Louis et 
al., 2007). Metabolic cross-feeding occurs when the products yielded from the 
metabolism of prebiotics by one bacterial species may then provide substrates to support 
the growth of other populations (Belenguer et al., 2006). 
 In light of cross-feeding in anaerobic communities, it is important that prebiotics 
can influence non-target populations in the gut microflora (Flint, Duncan, Scott, & 
Louis, 2007). MacFarlane et al. (2006) remark that inulin has also been associated with 
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increases in other bacterial genera: Roseburia, Ruminoccocus, and Eubacterium. Duncan 
et al. (2003) found that inulin was associated with increases in two groups of 
Clostridium-related bacteria and in Roseburia inulinvorans. Flint et al. state that 
Roseburia inulinvorans is regarded as potentially beneficial due to its butyrate-
producing capabilities; however, the health effects of modulating the other bacterial 
groups are generally not known.  
2.1.5.2 Inulin 
 Inulin is a heterogeneous blend of fructose polymers naturally present in a 
variety of fruits and vegetables, including wheat, onions, leeks, garlic, asparagus, 
Jerusalem artichokes, and bananas (Carabin & Flamm, 1999). Inulin has therefore has 
been part of the human diet for centuries. Inulin from chicory root is commercialized as 
a purified food ingredient, and always contains a small amount (up to 10 %) of naturally 
occurring sugars (Coussement, 1999). Inulin is also extracted commercially from stems 
of the blue agave plant (Waleckx, Gschaedler, Colonna- Ceccaldi, and Monsan, 2008). 
 Inulin is a generic term which represents all β (1← 2) linear molecules of 
fructans (a polymer of fructose monomers) of varying lengths, from 2 to 60 units 
(Niness, 1999; Roberfroid, 2007). Oligofructose and fructooligosaccharide (FOS) are 
synonymous names for the mixture of small inulin oligomers with degree of 
polymerization of less than 10 (a short length) (Roberfroid, 2007). As a partial 
hydrolysate of inulin, FOS is used as a food ingredient. Inulin and FOS are used in the 
food industry to replace fats and sugar (Coussement, 1999). Inulin is easier to tolerate 
than oligofructose in terms of gastrointestinal symptoms, since inulin is more slowly 
fermented (Coussement, 1999). 
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 The β (1← 2) linkage gives inulin the ability to resist digestion by human 
intestinal enzymes. The structure of inulin is below in Figure 1; the n represents the 
number of fructose monomers. 
 
Figure 2.1: Chemical Structure of Inulin (Fisch, 2008). 
 
 
 
 
 
 
  
 
2.1.5.2.1 Safety and Dosing of Inulin 
 According to Coussement (1999), most people can consume 10 g of inulin 
without any gastrointestinal side effects, whereas some individuals may experience some 
discomfort and rarely diarrhea. The fermentation of dietary fibre by anaerobic bacteria 
produces gas, including H2, CH4 and CO2, which may be related to complaints of 
distension or flatulence (American Dietetic Association, 2008). Carabin and Flamm 
(1999) conducted a review on the safety of inulin by evaluating numerous toxicological 
and clinical studies. They state that these studies have demonstrated no evidence of 
toxicity from inulin, and purport that real issue is not that of safety, but rather of 
gastrointestinal tolerance. The toxicological and clinical studies reported signs of 
gastrointestinal intolerance observed in healthy adults with intakes above 20–30 g.  
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 The actual tolerable intake of inulin appears to still be a topic of debate. The 
effect of adding 14 g/d of inulin to a low-fat spread was studied in seventy-two healthy 
women aged 20-36 years. The study was performed as a double-blind randomized 
crossover experiment with two periods of 4 weeks without any washout period. The 
degrees of discomfort from the gastrointestinal symptoms, including of rumbling in 
stomach, rumbling in gut, stomach cramps, gut cramps, bloating, and flatulence, were all 
ranked significantly higher in the inulin test period compared with the control test period 
(p<0.001). Throughout the experiment, discomfort from flatulence was the most 
profound symptom. Discomfort from flatulence was ranked as severe by 12 % of the 
volunteers when consuming the inulin spread and the participants did not adapt to 
consumption of the inulin over time (p<0.05) (Pedersen, Sandstrom, & van Amelsvoort, 
1997). 
 Davidson and Maki (1999) examined the effects of providing 3 servings of inulin 
containing foods per day to 25 male and female adults with hypercholesterolemia in a 
randomized, double-blind crossover study (three six-week periods of inulin or placebo, 
wash-out, and placebo or inulin. A total of 18 g/d of inulin was provided. 
Gastrointestinal discomfort was more common during the inulin phase than the placebo 
phase (5/21 participants reported no gastrointestinal side effects in the inulin phase, vs. 
13/21 participants in the control phase; p<0.003). The symptoms included flatulence, 
abdominal cramping, bloating, and changes in the frequency and consistency of bowel 
movements. The symptoms generally did not reduce in frequency or severity during the 
six weeks of treatment on inulin, indicating that the patients’ gastrointestinal systems did 
not adapt to the inulin. 
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 Kruse, Kleesen, and Blaut (1999) evaluated the effects of inulin on eight healthy 
adults under free-living conditions over a period of 10 weeks. They examined 
gastrointestinal compatibility, effects on fecal microflora, SCFA, and blood lipid 
variables. The subjects consumed a fat-reduced diet for a period of 64 days using inulin 
as a fat replacer. The amounts of inulin consumed by the subjects varied, as they were 
based on individual energy requirements. Participants consumed up to 34 g/d. Inulin 
significantly increased bifidobacteria and caused a moderate increase in the 
gastrointestinal symptoms of flatulence and bloating for the participants. These 
symptoms occurred 8–9 hours after intake of inulin. The formation of hydrogen as a by-
product of bacterial fermentation was deemed the likely cause of these symptoms. 
However, the authors emphasized that bifidobacteria are not capable of H2 gas 
formation.  
 In contrast to the findings of Pedersen et al. (1997), Kruse et al. (1999) observed 
adaptation of participants’ gastrointestinal systems to inulin supplementation. Even 
though the Pedersen group provided nearly half of the dose of inulin as Kruse et al., 
Pedersen et al. noted no adaptation of subjects to inulin. Thus, it appears that there is 
variability in the amount of inulin that is tolerable in healthy adults, and reports of 
adaptability of gastrointestinal systems to inulin supplementation are also inconsistent.
 Coussement (1999) states that individual variation in the sensitivity to inulin 
exists. Orafti, a European food company, developed three categories regarding 
sensitivity to fermentable carbohydrates (Table 2.3).  
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Table 2.3: Categories of Sensitivity to Fermentable Carbohydrates 
(Adapted from Coussement,1999) 
Category Reaction to fermentable carbohydrates 
I. Nonsensitive persons Can consume ≥ 30 g/d  without undesirable reactions 
II. Sensitive persons Can consume 10 g/d without undesirable reactions, 
but may experience reactions at ≥ 20 g/d 
III. Very sensitive persons Experience undesirable reactions at ≤ 10 g/d 
  
 2.1.5.2.2 Prebiotic Effects of Inulin: Bifidus Stimulation   
 Bouhnik et al. (1999) examined the dose-dependent bifidus stimulation in FOS 
supplementation for healthy adults. In interpreting the results of their study, it is 
important to recall that a longer chain inulin is more slowly fermented than FOS, 
therefore the bifidogenic effects would differ and the tolerance to inulin would be 
greater (Coussement, 1999). Bohnik et al. concluded that the optimal and well-tolerated 
dose of FOS that significantly increases fecal bifidobacteria in healthy adults is 10 g/d 
(p<0.05). At the dose of 20 g/d, flatus was more frequent and intense than at the 10g/d 
dose (p<0.05).  
 These results for healthy adults cannot be applied to patients with IPAA. The 
amount of inulin that is tolerable in patients with IPAA has only been evaluated by the 
Welters et al. (2002) trial, who did not report any side effects at 24 g of inulin per day.  
 
 2.1.6 Synbiotics 
 Synbiotics are a mixture of probiotics and prebiotics (Bengmark, 2001). The 
approach of mixing the two supplements improves the implantation and survival of the 
probiotics in the gastrointestinal tract. Synbiotics activate the metabolism and/or 
selectively stimulate the growth of one or a few health-promoting bacteria (Gibson & 
Roberfroid, 1995).  
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2.2 Relevant Diseases of the Colon 
2.2.1 Inflammatory Bowel Disease 
 Inflammatory Bowel Disease (IBD) is a relapsing and remitting condition of 
chronic inflammation at various sites along the gastrointestinal tract (GIT) lining, which 
can result in severe bouts of watery or bloody diarrhea and abdominal pain. IBD 
includes Crohn's disease and ulcerative colitis (UC) (Yantiss & Odze, 2006). IBD affects 
approximately 1 in 200 individuals in Canada (Crohn’s and Colitis Foundation of 
Canada, 2008). The inflammation of IBD results from a cell-mediated immune response 
in the GIT mucosa and the precise etiology is unknown, but it has been suggested that in 
patients with multifactor genetic predispositions, the normal intestinal (commensal) flora 
trigger an immune reaction (Wexner & Stollman, 2007).  
 The symptoms of UC and Crohn’s disease are similar, but they are quite different 
diseases. UC is limited to the mucosa of the intestinal tract, while Crohn’s disease 
involves much deeper mucosal tissue. UC only affects the colon and rectum, whereas 
Crohn's disease can occur anywhere along the digestive tract. Unlike UC, in which 
inflammation occurs uniformly throughout an affected area; Crohn's disease can develop 
in several places simultaneously, with healthy tissue in between (Wexner & Stollman, 
2007). 
 Medical treatment for IBD involves steroids and other immunomodulating 
systemic and topical drugs, such as 5-Aminosalicyclic acid and 6-mercaptopurine. All of 
these treatments may have serious adverse effects. One promising therapeutic agent for 
the treatment of UC is probiotics; researchers have shown positive results in several 
controlled trials (Wexner & Stollman, 2007). A minority of patients opt for elective 
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surgery of removing the entire colon and rectum, which has the potential to cure UC 
(Wexner & Stollman, 2007). 
2.2.2 Familial Adenomatous Polyposis 
 Familial adenomatous polyposis (FAP) is a rare inherited disease which is 
characterized by hundreds to thousands of polyps formed on the lining of the lower 
intestine (Galiatsatos & Foulkes, 2006) and accounts for less than 1% of all colorectal 
cancer cases (Vasen et al., 2008). The two main options of prophylactic removal of the 
large intestine are proctocolectomy with ileal pouch anal anastomosis (IPAA) and 
colectomy with ileorectal anastomosis (IRA) (Vasen et al., 2008). 
 
2.3 Ileal Pouch Anal Anastomosis  
2.3.1 The procedure of Ileal Pouch Anal Anastomosis 
 The ileal pouch anal anastomosis (IPAA) is a surgical procedure following total 
proctocolectomy for UC, Crohn’s disease, and FAP, in which the surgeon forms a 
functional reservoir of intestine for the accumulation of feces. The purpose of the 
reservoir is to avoid the need for a permanent discharging stoma for patients (Taylor, 
1986). The IPAA procedure involves removal of the colon and formation of a reservoir 
from 30 to 40 cm of ileum. The anal sphincter is preserved to maintain anal continence 
(Blumberg & Beck, 2002). The villi of the ileum after an IPAA adapt to their function 
and become more histologically similar to colonic mucosa (Winkler, 2003); the cells of 
the mucosa undergo a transformation from ileal to become colon-like. This cellular 
transformation is accompanied by the development of microflora that is qualitatively 
intermediate between the ileum and the colon (Stocchi & Pemberton, 2001). The first 
successful IPAA was performed in 1980 (Utsonomiya et al., 1980) and it has now 
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become the surgical procedure of choice for the management of UC and FAP (Welters et 
al., 2002). Oresland, Fasth, Nordgren, Akervall and Hulten (1990) measured pouch 
volumes of 67 patients over a 2-year period and found the mean pouch volume increased 
during the first year post-surgery, from 132 ml to 282 ml.  
2.3.2 Microbial Differences Before and After IPAA Surgery 
 One study compared patients with ileostomies as controls to patients with IPAA 
and determined that patients with IPAA had higher ratios of anaerobes: aerobes and 
higher concentrations of anaerobic gram-negative rods (Bacteriodes species) (Sandborn 
et al., 1995). Almeida et al. (2008) sought to indentify the microflora in patients (n=10) 
with severe UC pre-IPAA surgery and 2 and 8 months post-IPAA surgery. The authors 
found that no bacterium could be indentified that could be exclusively responsible for 
the maintenance of the inflammatory process in IPAA. The microflora underwent 
significant alterations post-IPAA surgery but returned to normal ileal values for some 
bacteria.  
2.3.3 Nutritional Guidelines for Patients with IPAA 
 Literature on food-related problems with IPAA surgery is scarce. Steenhagen, 
Roos, Bouwman, Van Laarhoven, and Van Staveren (2006), administered a survey to 
identify the foods causing intolerance and to determine the nature and severity of 
symptoms of 105 patients with IPAA. All of the patients reported intolerance to one or 
more foods. Spicy foods, cabbage, and citrus fruits and juice were the foods most often 
attributed to increased stool frequency (patient-reported), decrease stool consistency, or 
perianal irritation. Onions, cabbage, or leeks were reported by 28% of the patients to 
cause flatulence. The urgency of bowel movements was reported to be more intense 
after a cooked meal (45% of patients within ½ hour) than after sandwiches (15% within 
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½ hour). Foods reported to increase stool consistency were potato products, bread, and 
bananas. Based on these subjective reports, the researchers concluded that food 
intolerance is a common, but a mild problem after IPAA. They suggested that nutrition 
professionals should encourage patients to choose foods based on individual tolerance, 
rather than providing patients with a list of foods that may cause discomfort, as this may 
cause unnecessary avoidance of foods. 
  
2.3.4 Pouchitis and Other Outcomes of the IPAA Procedure 
 2.3.4.1 Pouchitis 
 Patients with IPAA may develop pouchitis. Pouchitis is inflammation of the 
pouch mucosa. It involves abdominal abdominal pain, urgency, bloody or mucous 
diarrhea, fever and/or general malaise (Turina et al., 2006). Patients with pouchitis have 
a varying range of clinical presentation, clinical course, and prognosis (Yamamoto-
Furosho, 2007). 
Pouchitis can be acute or chronic in nature (Winkler, 2003) and there are varied 
reports of the occurrence of pouchitis, reflecting varying degrees of accuracy and types 
of diagnostic evaluation (Stocchi & Pemberton, 2001). The incidence of pouchitis has 
been reported to range from 10% to 35% in the first 10 years after surgery, with a peak 
incidence at 18 months post-procedure (Blumberg & Beck, 2002). Other authors have 
reported even higher incidents of pouchitis, up to 59% (Simchuk & Thirlby, 2000).  
 Inflammation in pouchitis is thought to be caused by the mucosal invasion of 
bacteria, pathogenic toxins, or secondary changes, such as SCFA profile disruptions in 
the pouch (Lim, Sagar, Finan, Burke, & Schuster, 2006). The etiology and pathogenesis 
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of pouchitis is still debated, but the predominant theory of the pathogenesis of pouchitis 
is a microbial imbalance or dysbiosis of the pouch mucosa (Ohge et al., 2005).  
2.3.4.2 Pathogenesis of Pouchitis 
The predominant theory of the pathogenesis of pouchitis is a microbial 
imbalance or unstable microflora of the pouch (Ohge et al., 2005). The instability of the 
microflora in the pouch causes a disruption of the homeostasis, known as dysbiosis. The 
protection by mucus of the pouch epithelium layer is negatively affected by the 
increased activity of bacteria and host derived enzymes (Ruseler-van Ebden, Schouten, 
& van Lieshout, 1994).  
The role of microflora in the inflammation of pouchitis is suspected due to the 
differing response of patients with pouchitis to antibiotics such as metronidazole and 
ciproflaxin. In addition, use of probiotics such as VSL#3 can prevent the first onset of 
inflammation within the pouch (Lim et al., 2006). VLS is a mixture of viable bacteria 
(Vsl Pharmaceuticals Inc.) and specifically contains four strains of Lactobacillus (L. 
casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus ), three strains 
of Bifidobacterium B. longum, L. breve, and B. infantis), and Streptococcus 
thermophilus of the Streptocuccus salivarius subsp. (Elahi, Nikfar, Derakhshani, Vafaie 
& Abdollahi, 2007).  
 However, researchers have still failed to demonstrate any one organism or toxin 
responsible for pouchitis (Lim et al., 2006). As reviewed by Lim et al., several 
differences in the microflora composition of healthy pouches exist when compared to 
pouches afflicted with pouchitis. The combined results of several studies indicate that 
pouchitis is associated with increased counts of aerobic bacteria and decreased counts of 
anaerobic bacteria, Lactobacillus and Bifidobacterium (Brandi et al., 1992; Ruseler-van 
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Emben, et al., 1994). These authors noted the following microbial imbalances in 
pouchitis: increased clostridia, decreased bifidobacteria, and decreased lactobacilli. A 
reduction in bifidobacteria and lactobacilli is associated with decreased SCFA 
production and consequently a less acidic environment. A relatively high pH in patients 
with pouchitis is a symptom of the instability of the microflora (Ruseler-van Embden et 
al., 1994).  
 Kuisma et al. (2003) compared 11 patients with optimal pouch function to 21 
patients with pouchitis history following IPAA construction for UC. No significant 
differences existed in mean nutrient intake, composition of fecal bile acids, or microbial 
tissue biopsy cultures between the groups. Dietary intake was not significantly 
correlated to the presence or absence of pouchitis. Those patients with optimal outcome 
tended to have more benign disease course of UC than patients with a history of 
pouchitis. In those patients with histories of pouchitis, fecal concentrations of both 
anaerobes and aerobes were significantly higher (p=0.007) than patients with optimal 
outcome. Low intake of lactose was associated with sulfomucin predominance. A 
negative correlation existed between fecal aerobes and dietary lactose consumption. 
Kuisma et al. concluded that a higher total load of fecal anaerobic bacterial flora is 
strongly associated with the degree of villous atrophy, colonic metaplasia, and 
inflammation activity after IPAA surgery. Interestingly, Kuisma et al. also found an 
association between dietary lactose, fecal bacteria, and pouch morphology and suggested 
that lactose may have prebiotic properties. Lactose was inversely correlated with total 
aerobes (p=0.019).  
 Hydrogen sulfide (H2S) has also been proposed as a fecal bacteria product that 
may cause pouchitis. Ohge et al. (2005) investigated H2S release and SRB counts in 
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pouch contents to determine if H2S correlates with pouchitis. During an eight-month 
period, patients with IPAA after proctocolectomy for FAP (n=5) and UC (n=45) 
provided fecal samples for analysis. Release of H2S when pouchitis was active or had 
occurred in the past year was significantly higher (p <0.05) than when pouchitis had 
never occurred or had been inactive. H2S release from pouch contents of UC patients not 
receiving antibiotics was five to ten times more rapid than observed for FAP patients, 
possibly suggesting a difference in sulfide metabolism between these groups. 
 In one study, SRB appeared to be exclusive to IPAA patients with an UC 
background only. SRB were not found in the pouches of patients with a background of 
FAP (Duffy et al., 2005). Levels of Lactobacilli, Bifidobacterium, Bacteriodes, 
Clostridium perfringens, enterococci, and coliforms were similar in both UC and FAP 
patients. Because pouchitis mainly affects patients with a UC background, and SRB 
appear to be exclusive to UC pouches, it is postulated that SRB may play a role in the 
pathogenesis of pouchitis (Duffy et al., 2005). 
 Despite the numerous studies implicating the role of dysbiosis in the 
pathogenesis of pouchitis, some researchers dispute the role of dysbiosis. Sandborn et al. 
(1995) found no differences in the fecal concentrations of bacteria, bile acids, or SCFAs 
in patients with pouchitis versus patients without pouchitis, and Sandborn et al. 
concluded that these factors cannot be the sole cause of pouchitis. Although Lim et al. 
(2006) do not address this specific article in their review; they do address other studies 
that do not show differences in bacterial concentrations in patients with pouchitis 
compared to those without. Lim et al. criticize these studies for providing poor 
categorizing and classification of pouchitis. However, Lim et al. also criticize the studies 
that support the theory of dysbiosis causing pouchitis. They note slight differences in the 
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candidate species or shifts in flora. Lim et al. conclude their review in stating that the 
evidence that dysbiosis is a cause of pouchitis is still poor and propose the need for more 
studies to determine if there is an unidentified pathogen, a broad imbalance of bacterial 
populations, or an exaggerated host response to commensal bacteria (the bacteria that is 
normally present in the intestines). They suggest future studies include proper selection 
of pouchitis patients according to established criteria and better culture and molecular 
techniques to study bacterial flora to expand the evidence of the dysbiotic theory of 
pouchitis. 
 Komanduri, Gillevet, Sikaroodi, Mutlu, and Keshavarzian (2007) used cloning 
and sequencing of the length heterogeneity polymerase chain reaction amplicons to 
evaluate the microflora of 20 post-IPAA surgery patients (range 1-5 years post-IPAA 
surgery). Komanduri et al. conclude that their data provide direct evidence of the role of 
microflora in the pathogenesis of pouchitis. They found an increased presence of 
Fusobacter and Enteric species associated with the presentation of pouchitis. In addition, 
the authors found decreased presence of Streptococcus species in inflamed pouches.  
 Another, less favored theory of pathogenesis is the belief that fecal stasis causes 
chronic recurring overgrowth of bacteria. However, critics of the fecal stasis theory 
argue that stasis as a cause of pouchitis is not likely in the absence of sphincter spasm, 
stenosis, or impaired evacuation of feces (Winkler, 2003). Kroesen et al. (2006) 
examined a theory of bacterial permeation of the pouch. They observed increased 
bacterial permeability in pouches of those patients with pouchitis (p< 0.001) but they 
were unable to link the permeability to decreased function of the pouch and did not state 
if the bacterial permeability was a cause of pouchitis or if it was as a results of pouchitis. 
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 Disagreement exists on the factors that influence the risk of developing 
pouchitis. Simchuk and Thirlby (2000) performed a retrospective review of 114 patients 
who underwent IPAA by a single surgeon. Stool frequency was 6.1 ± 0.2 per day and the 
incidence of pouchitis occurred in 67 patients (59%). Patient gender was significantly 
associated with the incidence of pouchitis 74% of women and only 47 % of men 
developed pouchitis (p = 0.008). Duration of follow-up was another factor; at 6 months 
post-surgery 27% of patients developed pouchitis, at one year 37%, and at 3 years 50% 
(p=0.02). However, Stocchi & Pemberton (2001) state that age, gender and 
postoperative sepsis do not appear to have an influence on the risk of developing 
pouchitis. Although pouchitis occurred in more than half of the patients reviewed, the 
mean patient satisfaction with the procedure was high, 8.4 (on a scale of 0 being 
dissatisfied and 10 being extremely satisfied).  
 Lovegrove et al (2006) performed a meta-analysis of studies comparing the 
outcomes of IPAA surgeries for patients with FAP versus patients with UC. The 
occurrence of pouch fistulation was significantly increased in those patients with UC 
(10.5% vs. 4.8%; p< 0.001), and the incidence of pouchitis, which was significantly 
greater in the UC patients (30.1 % vs. 5 %; p< 0.001). Stool frequency was also higher 
in the UC patients; on average UC patients had one more bowel movement per 24 hours 
than FAP patients.  
 Similarly to the findings on UC, smoking appears to reduce the risk of pouchitis. 
Pouchitis afflicts patients with a history of UC and is uncommon in patients with FAP, 
supporting a view that pouchitis is a form of UC that has recurred in the ileal pouch 
(Stocchi & Pemberton, 2001). In addition, immunologic alterations in pouchitis 
resemble the alterations in UC: cytokine production of IL-1β, IL-6, IL-8 and tumor 
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necrosis factor-α (Stocchi & Pemberton). Yet, the immunologic component of the 
pathogenesis of pouchitis has not been clearly established, as Schmidt et al. (2006) 
contradicts Stocchi & Pemberton in stating that cytokine and chemokine patterns in 
pouchitis are not typical of UC. 
 Although the etiology and the dysbiotic theory of the pathogenesis of pouchitis 
has not yet reached consensus by leading IPAA researchers, there is still sufficient 
evidence that increasing the counts of Lactobacillus and Bifidobacterium bacteria may 
restore the microbial balance of the pouches. Both prebiotics and probiotics are agents 
that could increase the levels of beneficial bacteria. Prebiotics and probiotics are not 
known have any harmful effects and are being considered as an alterative treatment for 
pouchitis to recolonize the pouch with beneficial bacterial (Winkler, 2003). 
 2.3.4.3 Quality of Life 
 The poor quality of life (QOL) of UC patients improves in most clinical studies 
after the IPAA procedure. Nevertheless, QOL and bowel function is still not considered 
normal, since many patients have problems with urgency, leakage, nocturnal soiling, 
sexual dysfunction, and pouchitis (Lichtenstein, Cohen, Yamashita & Diamond, 2006). 
The occurrence of pouchitis has a particularly negative impact on patients following 
IPAA. Over a ten-year period, 68 patients were administered Global QOL 
Questionnaires and telephone interviews. Overall QOL, satisfaction with IPAA surgery, 
subjective health, and energy levels were significantly lower in patients with chronic 
pouchitis (p<0.01) than patients without pouchitis (Turina et al., 2006). 
 2.3.4.4 Pouchitis Disease Activity Index 
 The Pouchitis Disease Activity Index (PDAI, Table 2.4) is a diagnostic 
instrument that was developed by Sandborn et al. (1994) to assess pouchitis in an 
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objective and quantitative manner. PDAI is the most commonly used diagnostic 
instrument in pouchitis research and consists of three principle component scores: 
symptom, endoscopy, and histology (Shen et al., 2003). Patients who are graded a score 
of seven or more are classified as having pouchitis. In comparison to the previously 
established diagnostic scoring systems for pouchitis, the PDAI is more sensitive in 
detecting pouchitis (Sandborn et al., 1994).  
 
Table 2.4: The Pouchitis Disease Activity Index  
(Developed by Sandborn et al., 1994) 
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 Shen et al. (2003) criticize the PDAI because its practical use is limited due to 
the cost of endoscopy and histology. Also, the PDAI is limited due to complex 
calculation and a time delay in diagnosis in determining scores. Accordingly, Shen et al. 
developed a Modified PDAI (mPDAI) which omits histological evaluation. They tested 
their instrument to determine if removing the measure of histology would affect the test 
sensitivity or specificity. They concluded that the mPDAI provides similar specificity 
(100%) and sensitivity 97% compared to the PDAI. The mPDAI provided 0% false-
positives and 4% false-negative tests (1 of 27). Although Shen et al. (2003) were able to 
address some of the impracticality, expense, and time delay of using the PDAI by 
eliminating the histological measures; they were not able to omit the endoscopic 
component. Symptoms, endoscopy and histology do not correlate with each other, and 
consequently one can not rely on a single component, such as symptom scores, to 
accurately diagnose pouchitis (Shen et al., 2003).  
   
2.4 Treatment of Pouchitis 
2.4.1 Conventional Treatment 
 Antibiotics such as metronidazole, ciproflaxin, tetracycline, clarithromysin, 
amoxicillin/clavulanic acid, and rifaximin are used to treat pouchitis (Winkler, 2003). 
Other treatment regimes may include topical steroids, suppositories, enemas, and anti-
diarrheal agents (Winkler, 2003). Conventional treatment of pouchitis with antibiotics is 
not satisfactory, as relapse is common and antibiotics inflict negative alterations of the 
normal microflora of the intestines (Winkler, 2003). Therefore, effective treatments that 
also improve the microfloral balance of the IPAA are more attractive than the 
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conventional options. The following sections will review probiotics and prebiotics, two 
treatments which could potentially achieve this goal.  
2.4.2 Probiotics for the Management of Pouchitis 
According to Hedlin et al. (2007), the most convincing evidence for the use of 
probiotics in pouchitis comes from randomized, double-blind, placebo-controlled trials 
of VSL# 3. VSL #3 has two innovative characteristics: a very high bacterial 
concentration of 300 billion live bacteria/g and a mixture of bacterial strains which 
creates the potential for synergistic relationships to enhance the suppression of 
pathogenic agents (Gionchetti et al., 2000). 
Elahi et al. (2007) performed a meta-analysis of controlled clinical trials that 
examined the effect of probiotics in preventing pouchitis as defined by the Pouchitis 
Disease Activity Index (PDAI). Only five randomized, placebo-controlled clinical trials 
were included in the meta-analysis; four studies investigated VSL #3 and one study 
examined Lactobacillus rhamnosus GG. The majority of the randomized controlled 
trials reviewed were limited by small sample sizes and therefore a low power in 
determining a true positive effective of probiotics (Elahi et al., 2007). They also only 
chose similar studies for their meta-analysis to estimate a combined effect. The pooling 
of the results from the trials reviewed by Elahi et al. yielded an odds ratio of 0.04 with a 
95% CI of 0.01–0.14 (P<0.0001) in the treatment group in comparison with the placebo 
group.  
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Table 2.5: Summary of the Trials Included in Elahi et al. Meta-analysis 
(Adapted from Elahi et al., 2007)   
Study Number of 
Participants 
Type and 
Dose of 
Probiotic 
Median 
Months of 
Follow-up 
Reported 
Pouchitis: 
Control 
Reported 
Pouchitis: 
Treatment  
Gosselink 
et al. 
(2004) 
200 Lactobacillus 
rhamnosus 
GG 
1.4 x 1010 
CFU/d 
 
60 
(control); 
32 cases 
46/85 4/42 
Gionchetti 
et al. 
(2000) 
 
40 VSL #3 
6 g/d 
4 20/20 3/20 
Gionchetti 
et al. 
(2003) 
 
40 VSL #3 
6 g/d 
12 8/20 2/20 
Mimura et 
al. 
(2004) 
 
36 VSL #3 
6 g/d 
12 15/16 3/20 
Kuhbacher 
et al. 
(2006) 
15 VSL #3 
6 g/d 
2 5/5 0/10 
 
Elahi et al. (2007) concluded that their meta-analysis confirmed that probiotics 
are beneficial in the management of pouchitis and suggested that further research should 
contain sufficient sample sizes and should be focused on determining the proper dose 
and timing of probiotic administration. They warn that the results should be interpreted 
carefully, since the meta-analysis did not allow for adjustment of clinically relevant 
variables such as characteristics of the patients (i.e. age and gender), duration of the 
therapy, and choice of probiotic supplement. Other substances present in fermented 
products may also have an effect on the results.  
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No adverse effects were reported by Gionchetti et al. (2000), Kuhbacher et al. 
(2006), or Gionchetti et al. (2003). Mimura et al. (2004) reported that one of the twenty 
patients receiving the VSL #3 dropped out due to abdominal cramps, vomiting, and 
diarrhea.  
The Gosselink et al. (2004) trial should not have been included in their meta-
analysis, based on their criteria of requiring the trials to be randomized. Gosselink et al. 
performed a non-randomized study of IPAA patients (n=85 controls versus n=42 
patients on the probiotic Lactobacillus rhamnosus GG contained in a fermented 
product). Patients who had surgeries performed between March 1996 and March 2001 
were given the probiotic. Patients who had surgeries performed between October 1986 
and March 1996 never used any probiotics and therefore served as the control. 
Therefore, this study is not randomized and should not be included in the Elahi et al. 
meta-analysis. Nevertheless, the results of are promising: first episodes of pouchitis were 
observed less frequently in the group taking the probiotic. The cumulative risk at 3 years 
was 7% (probiotic group) vs. 29% (control) (p=0.011). They concluded that a daily 
intake of 1-2 x 1010 Lactobacillus rhamnosus GG should be recommended to IPAA 
patients to delay the onset of pouchitis. 
As previously mentioned, several studies are not included in the meta-analysis by 
Elahi et al. (2007). Most studies were excluded from the meta-analysis because they 
were not randomized or double-blinded, or because their sample sizes were too small. 
Other studies were excluded because they did not examine the desired outcome measure 
of pouchitis defined as a PDAI ≥ 7. However, several of these studies still warrant 
discussion.  
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Laake et al. (2005) examined the effects of a fermented milk product containing 
live lactobacilli (La-5) and bifidobacteria (Bb-12) for 4 weeks on 69 patients with IPAA 
in an open-label intervention. They observed a significant reduction in endoscopic score 
(p= 0.0001) and a significant increase in lactobacilli (p= 0.017) and bifidobacteria (p= 
0.006). Patients with a history of UC experienced significantly decreased symptoms 
(involuntary defecation, leakage, abdominal cramps, need for napkins, fecal number and 
consistency, mucus and urge to evacuate stools) during the intervention. 
Kuisma et al. (2003) conducted a three-month, randomized, double-blind, 
placebo-controlled prospective trial of Lactobacillus GC supplementation (n=20) which 
demonstrated that the probiotic was effective in changing participants’ pouch intestinal 
flora; the probiotic was associated with an increased ratio of total fecal lactobacilli to 
total fecal anaerobes (p=0.03). But, the probiotic therapy was ineffective as the primary 
therapy. There were no clinical improvements for the treatment group based on the 
PDAI or the total anaerobes or aerobes of fecal or tissue biopsy samples. The authors 
suggest the need for more clinical trials to determine the proper dosage and placement of 
probiotics within a pouchitis treatment regimen.  
Shen et al. (2005) studied VSL #3 in maintaining antibiotic-induced remission in 
pouchitis patients (n=31). All patients received 2 weeks of the antibiotic Ciprofloxacin 
and subsequent treatment with the probiotics. At the 8 month follow-up, 25/31 patients 
had discontinued taking the probiotics due to either recurrent symptoms (23/31; 74.2%) 
or to intolerable adverse effects (2/31; 6.5%). One patient developed bloody bowel 
movements immediately after starting the treatment, and one patient developed severe 
constipation, bloating, and gas. The remaining 6/31 (19.4%) patients underwent clinical 
and endoscopic evaluation, and their PDAI scores were not significantly different from 
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baseline (p= 0.27). Shen et al. concluded that only a minority of the patients were 
compliant on long-term maintenance probiotic therapy and suggest the need for more 
clinical trials on the safety and efficacy of probiotics before incorporating them into 
daily clinical practice for managing pouchitis. One limitation of this study was the fact 
that patients had to purchase, store, and self-administer the VSL #3, which may have led 
to decreased compliance, since probiotics are costly. However, this reflects a realistic 
setting of the use of probiotics in pouchitis.  
In summary, amongst the mixed results of probiotic trials for pouchitis, some 
positive convincing evidence exists. Although most trials did not report any adverse 
effects, Mimura et al. (2004) and Shen et al. (2005) did report some side effects that 
suggest more investigation on the safety and dosing of probiotics for the prevention and 
management of pouchitis is needed.  
 
2.4.3 Prebiotics for the Management of Pouchitis 
 To date, there have only been two studies of prebiotics for the management of 
pouchitis published. Both studies implement the prebiotic inulin and they will be 
discussed in detail.  
 Welters et al. (2002) conducted a three-week cross-over design study of twenty 
patients with pouchitis receiving either large doses of inulin or placebo (24 g). Fecal 
samples were analyzed for pH, SCFAs, microflora and bile acid. Compared to the 
placebo, significant improvements on inulin included increased butyrate concentrations 
(p= 0.01), lowered pH (p= 0.02), decreased numbers of Bacteriodes fragilis (p= 0.02), 
and decreased concentrations of secondary bile acids (p= 0.01 for deoxycholic acid and 
p= 0.04 for ursodeoxycholic acid). The researchers concluded that inulin 
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supplementation leads to decreased inflammation of the pouch mucosa (Welters et al.). 
No adverse effects were studied, with the exception one participant who dropped-out of 
the study due to lactose intolerance from the lactose-containing drink in which the inulin 
was administered. However, the authors did not describe how the lactose intolerance 
was diagnosed, so it may be possible that the symptoms of lactose intolerance could 
actually be due to side effects of the inulin supplementation.  
 This short-term study by Welters et al. (2002) provides evidence for the effect of 
inulin supplementation at the microbial level. However, no studies have addressed the 
effectiveness of long-term inulin supplementation on the reduction of pouchitis and 
pouch problems. In addition, to our knowledge, no one has investigated the effect of 
inulin supplementation on the quality of life of individuals who are afflicted by chronic 
pouchitis.  
 The Welters et al. (2002) study is frequently cited as evidence for the use of 
prebiotics in inflammatory bowel disease and pouchitis. The other study of inulin for 
pouchitis (Meijer et al., 2000) is actually the exact same study that was published by 
Welters et al., but with a very different spin on the results. It is also important to note 
that Welters was the second author for the Meijer et al. article, and both articles are 
published in Diseases of the Colon and Rectum. Meijer et al. does refer to the positive 
results by Welters et al. as “unpublished data”, but Welters et al. does not refer to the 
Meijer et al. article.  
 In contrast to the conclusions of the Welters et al. article (2002), in the Meijer et 
al. (2000) article, the authors concluded that inulin did not influence inflammation or 
have an effect on pouch mucosal functioning because neither epithelial gene expression 
nor epithelial homeostasis was significantly changed by inulin supplementation. 
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Mucosal morphology, epithelial cell proliferation and cell death were not altered by 
inulin supplementation. It is not clear why the results of the same three-week trial would 
be published with two separate and contrasting conclusions. 
 Croagh et al. (2007) take a very different approach to the use of inulin in 
pouchitis. They hypothesized that fermentable oligo-, di, and monosaccharides and 
polyols (FODMAPs), which are poorly absorbed short-chain carbohydrates, should 
increase fecal output following IPAA or ileorectal anastomosis (IRA) due to their 
osmotic effects. FODMAPs include fructans (inulin), free fructose and lactose (in cases 
where maldigestion is present), and polyols such as sorbital. Croagh et al. studied 15 
patients (13 with IPAA and 15 IRA) to determine the effect of reducing FODMAPs. 
Therefore, in contrast to Meijer et al. (2000) and Welters et al. (2002), inulin was treated 
as an agent that causes pouch problems as opposed to protecting against pouch 
problems, and they aimed to determine the effect of removing inulin and other short-
chain carbohydrates.  
 The 15 patients underwent symptomatic and dietary evaluation before and after 
the low-FODMAP diet and carbohydrate malabsorption was measured by breath H2 
tests. Pouchitis was assessed clinically/endoscopically or by fecal lactoferrin. These 
methods were limited, since the authors did not use the PDAI for the pouchitis diagnosis 
and did not have histological measures. Additionally, by reducing a combination of 
factors in the diet makes it difficult to isolate the effects of the nutrient of interest, inulin. 
However, the results of the trial are interesting: overall, none of the patients who had 
pouchitis showed improvement with the low FODMAP diet. However, median daily 
stool frequency decreased significantly; from 8 bowel movements/day to 4 bowel 
movements/day (p= 0.001) in patients without pouchitis. Again, since a combination of 
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dietary factors was reduced, we cannot conclude from this study that decreasing inulin 
specifically would reduce the pouch problem of frequency, but it is possible that it could 
be a contributing factor. 
2.4.4 Synbiotic Therapy for the Treatment of Pouchitis 
 The literature on synbiotic therapy for the management of pouchitis is limited to 
an abstract by Friedman and George (2000). Ten patients with either refractory pouchitis 
or requiring long-term antibiotic uses were treated with Lactobacillus GG and the 
prebiotic FOS (fructooligosaccharide; amount not listed), one capsule twice daily for 
one month. All ten patients had reversal of macroscopic and endoscopic alterations and 
complete suppression of their symptoms. They concluded that prebiotic and probiotic 
therapy provides effective adjunctive therapy for patients with refractory pouchitis. 
 
2.5 Summary 
 In summary, IPAA is the surgical procedure of choice for the management of UC 
and FAP; however, the quality of life of some patients is negatively affected by a 
mucosal inflammation known as pouchitis. The etiology and pathogenesis of pouchitis is 
still debated in the literature, but the predominant theory is a microbial imbalance or 
dysbiosis of the pouch mucosa. Balanced microbiota contain high levels of bacteria from 
the genera Bifidobacterium and Lactobacillus, which are primarily carbohydrate 
fermenting, do not contain any known pathogens, and are associated with colonization 
resistance to pathogens. Both prebiotics and probiotics are agents that could increase the 
levels of these beneficial bacteria to restore microbial balance.  
 Although the results of probiotic trials for pouchitis are mixed, the majority of 
trials provide convincing evidence for probiotic supplementation. In contrast, the 
37 
research available on prebiotics and synbiotics for pouchitis treatment and prevention is 
very limited. The only prebiotic studied for pouchitis is inulin, and there is insufficient 
data to determine the acceptable dose of inulin for patients with IPAA. However, inulin, 
at 10 g/d, appears to cause the least discomfort in most healthy adults and has a 
significant bifidogenic effect at this dose.  
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CHAPTER 3 
RESEARCH METHODS 
 
3.1 Study Design 
 The study was initially approved as a 12-month, randomized, placebo-
controlled, double-blind trial. Participants with IPAA were to be recruited from Royal 
University Hospital patient health records and from one local surgeon’s referrals. 
Several amendments were made to the original design. The researchers felt that a 12-
month period might create subject burden, so the study was shortened to seven months, 
and included a one-month period for baseline measurements. The sample size goal was 
25 participants. To create balanced groups with a small sample size, the participants 
were matched to either the placebo or control, as opposed to randomization.  
 
3.2 Ethical Approval 
 Approval for this study was granted by the Biomedical Research Ethics Board 
of the University of Saskatchewan in Saskatoon, Saskatchewan (Bio-REB #06-65) and 
the Saskatoon Health Region (Appendix 1). The study coordinator signed a Non-
Disclosure Agreement to ensure that the information contained in the health records 
reviewed was kept confidential. Written informed consent was provided by the 
participants (Appendix 2). 
 
3.3 Participant Inclusion and Exclusion Criteria  
 Patients of both genders aged 18-75 years with recurrent pouch problems or 
pouchitis were eligible for enrollment. Patients who did not have documented pouch 
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problems or pouchitis were excluded. Patients with Crohn’s disease were excluded 
because their condition affects the ileum. In addition, patients with diabetes mellitus 
were also excluded as non-resistant maltodextrins can affect blood glucose 
concentrations, as maltodextrin contains 9.4 g of carbohydrate per 10 g dose. 
 
3.4 Recruitment 
 To assess for eligibility, Health Records of the Saskatoon Health Region 
retrieved health charts patients with a history of the IPAA procedure. A review was 
conducted of 94 health charts of patients in the Saskatoon Health Region who had 
received the IPAA procedure in the past ten years. In addition, a surgeon who 
specializes in gastroenterology referred several of his patients to the study. A letter 
requesting referrals was also sent to all surgeons who may have conducted IPAA 
procedures; however, no additional referrals were received.  
 If a patient was eligible for the study, an information package containing a letter 
of invitation to the study and a consent form were sent to their home address 
(Appendices 2 and 3). Patients were followed up by a telephone call after the 
information package was mailed-out. During the follow-up call, details of the study and 
consent form were reviewed, and questions that potential participants had about 
eligibility and allowance for taking other medications and supplements during the study 
were answered. Contact information was provided and interested patients were 
encouraged to contact researchers if they had any further questions. If patients were 
interested in participating in the study, they were requested to complete and return the 
consent form to the study coordinator.  
 
40 
3.5 Randomization of Participants 
 Participants were matched in order of priority by 1) time passed since pouch 
surgery, 2) gender, 3) diagnosis (UC or FAP), and 4) comorbid medical conditions. The 
participants were matched to either Group A or Group B. The treatment allocation was 
blinded to the participants and the researchers. 
 
3.6 Study Protocol 
 3.6.1 Supplement Dosing 
 The first month of the study was the baseline period. Participants did not 
consume any supplements for this month. Following the baseline period, the participants 
received a low-dose supplement of 5 g/d for of either the active treatment of inulin or a 
placebo of non-resistant maltodextrin for two weeks. If the low-dose supplement was 
tolerated, the participants then received a high-dose of 10 g/d of the same supplement for 
an additional five and a half months.  
 The inulin used in this study was Frutafit® CLR provided by Sensus America 
LLC (Monmouth Junction, JJ, USA). The Frutafit® CLR inulin is a mixture of 
oligosaccharides of 8 to13 monomers in length. The maltodextrin, Globe Plus® 18 
dextrose equivalents (DE), was provided by Corn Products International, Inc. (Casco 
Incorp. Etobiocoke, Ontario, Canada). Maltodextrin is a highly digestible dextrin that 
was selected as the placebo because it is a white, dissolvable powder that resembles 
inulin in appearance and taste. The inulin and maltodextrin were weighed on an 
electronic scale and placed in individual plastic sachets by the research assistant and the 
study coordinator. Participants were instructed to dissolve the supplement in a hot 
beverage. 
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3.6.2 Compliance 
 Participants were asked to mark in their study diaries whether or not they 
consumed the treatment each day, and also provided reasons for any missed doses. 
Compliance was calculated as a percent of days per period that the full dose was 
consumed. 
 
3.7 Data Collected 
 3.7.1 Demographic Data 
 Demographic data collected through Health Records on the participants included 
gender, age at baseline, date since IPAA surgery, comorbid medical conditions, and 
diagnosis. 
 3.7.2 Assessment of Safety and Symptoms 
 For each day of the study, including the baseline period, the low-dose 
supplementation stage, and the high-dose supplementation stage, the participants were 
asked to record any symptoms they experienced in a Symptom Diary (Appendix 4). The 
participants were asked to return the Symptom Diary as soon as it was completed. 
During the supplementation stages, participants were asked to report any adverse effects 
immediately to the research coordinator. 
 The participants recorded the following data in the Symptom Diary:  
1.  Ingestion of the supplement 
2.  Subjective Overall Health Rating 
3.  BM frequency (number of bowel movements per 24 hour period) 
4.  Any symptoms associated with pouchitis  
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 Participants were asked to record if they experienced the symptoms of bleeding 
(defined as blood in feces and upon wiping), fecal urgency (defined as the urgent feeling 
of need to defecate), abdominal cramping and pain, diarrhea and fever. In addition, 
participants were instructed to record any other symptoms they experienced. For the 
Subjective Overall Health Rating, the participants recorded their subjective overall 
health in their study diary daily as either: 5= Excellent, 4= Very Good, 3= Good, 2= Fair 
and 1= Poor. 
 Participants were to record any medications or other supplements they took 
during the study on the Medications page of their diary (Appendix 8). Any supplements 
and medications that a participant was taking at baseline were permitted during the 
treatment period. 
 
 3.7.3 Assessment of Quality of Life 
 Participants’ quality of life was assessed using the Short Inflammatory Bowel 
Disease Questionnaire (SIBDQ) (Appendix 5). The SIBDQ measures physical, social, 
and emotional status (Jowett, Seal, Barton, & Welfare, 2002) and was developed and 
validated to assess health related quality of life for patients with inflammatory bowel 
disease. Each participant’s total score (all 10 items) on the SIBDQ was also compared at 
baseline and post-supplementation. For each SIBDQ question, a score of 1 is a low 
quality of life score, and a 7 is a high quality of life score. Thus, an increase in SIBDQ 
scores represents an increase in quality of life. 
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3.8 Data Analysis 
 3.8.1 Sample Size Calculation 
 The sample size goal of n= 40 was based on two studies by Gionchetti et al. 
using probiotics in patients (n=40) with pouches (Gionchetti et al., 2000 and Gionchetti, 
et al., 2003).  
3.8.2 Statistical Analysis 
 All Statistical Analysis was performed using Office 2003 Excel and SPSS 16.0. 
A p-value of < 0.05 (two sided) was used to denote statistical significance. For each test, 
the inulin group was compared to the placebo group. A paired-t test was used to 
determine statistical difference between group means for SIBDQ scores. Each 
participant’s total score (all 10 items) on the SIBDQ was also compared at baseline and 
post-supplementation. Repeated measure ANOVA was used to determine statistical 
difference between group means for the symptoms, at three measures: baseline, 5 g dose 
supplementation and 10 g dose supplementation. 
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Health charts reviewed for 
eligibility (n=93)
Enrolled (n=9) 
 
Excluded (n= 84) 
Did not meet inclusion criteria (n= 69) 
Refused to participate (n= 10) 
Not contacted due to early cessation of study (n= 5)  
CHAPTER 4 
RESULTS 
4.1 Participant Flow 
 Figures 4.1 and 4.2 depict the flow of participants through all stages of the trial. 
Only 24 (25%) of the 93 patients met the inclusion criteria. Of the 24 eligible patients, 9 
consented to participation in the study, which represents a 37.5% participation rate 
(Figure 4.1).  
 
Figure 4.1 Schematic of Recruitment 
 
 
 
 
 
 
 
 
 
 Figure 4.2 shows the flow of participants through allocation, baseline 
measurement, treatment, follow-up and analysis. The nine participants were matched to 
the two different arms of the study and baseline data was collected on all participants. 
One of these participants, P-09, was diagnosed with Crohn’s Disease at the start of 
treatment period and was consequently excluded from further participation. Another 
participant, P-07, was deemed a special case. This special case participant was placed on 
the active treatment of inulin rather than matched to either group for ethical reasons. The 
participant was experiencing extreme abdominal discomfort to the point of wishing to 
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reverse the IPAA procedure. The research team felt it was unethical to place the 
participant in the placebo arm of the study, when a possible treatment was available, 
which could potentially avoid surgery. In addition, this participant was only asked to 
provide two (rather than four) weeks of baseline data. The rationale for a shorter 
baseline period was to provide the potential treatment as soon as possible, since this 
participant was in so much discomfort.  
 The participants (not including the participant with Crohn’s disease and the 
special case) started either the blinded low-dose treatment (5 g of inulin) or placebo, 
then subsequently received the high-dose treatment (10 g of inulin or placebo) two 
weeks later.  
 Two participants in the same high-dose arm discontinued taking the treatment 
due to significant side effects including cramping, abdominal discomfort, severe gas, 
small amounts of blood in feces, and upon wiping. At this point, the Biomedical 
Research Ethics Board was alerted and the Principle Investigator unblinded the study. It 
was determined that the participants who were experiencing significant side effects were 
in the inulin group; therefore, the researchers decided to stop both arms of the treatment 
intervention and terminate the study. All participants were informed of the early 
cessation of the study and were asked to submit their data. All participants (n= 9) 
submitted their study diaries, and seven participants submitted their intervention SIBDQ. 
One participant did not submit their SIBDQ data. Figure 4.2 shows the participant flow 
in the study. 
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Discontinued intervention (n=0) 
Lost to follow-up (n=0) 
*Remaining participants did not 
complete the full 5.5 month course 
of high dose due to early cessation 
of the study 
Intervention 
High Dose 
Discontinued intervention (n=2)* 
Lost to follow-up (n=0) 
*All remaining participants did not 
complete the full 5.5 month course 
of high dose due to early cessation 
of the study 
Follow-Up 
Analysis  
Figure 4.2: Flow of Participants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blinded intervention (n=4) 
Unblinded intervention (n=1) 
Allocated to intervention (n= 5) 
Blinded intervention (n=3) 
Did not receive intervention (n=1): 
excluded due to Crohn’s 
Allocated to intervention (n= 4) 
Baseline 
Measurement
Analyzed (n= 3) 
Excluded from analysis (n= 0) 
Enrolled participants (n=9) 
Allocation 
Provided baseline data (n= 5) 
Lost to follow-up (n=0)
Provided baseline data (n= 4) 
Lost to follow-up (n=0) 
Analyzed (n= 5)** 
Excluded from analysis (n= 0) 
**One participant did not complete 
the SIBDQ at intervention
Baseline 
Analysis
Baseline analyzed (n=5) 
Excluded from analysis (n=0)
Baseline analyzed (n=4) 
Excluded from analysis (n=0) 
Intervention 
Low Dose
Blinded intervention (n=4) 
Unblinded intervention (n=1) 
Received blinded intervention 
(n=3) 
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4.2 Participant Characteristics 
 The participant characteristics are compared for the inulin group vs. the placebo 
group in Table 4.1.  
 
Table 4.1: Comparison of Participant Characteristics by Allocated Treatment  
 Total participants  (n= 9) 
Inulin group 
(n= 5) 
Placebo group 
(n= 4) 
Mean Age (Years) (Range) 43.8 (20-60) 44.6 (20-60) 42.8 (25-57)
Average years since surgery (SD) 3.9 (+/-13.9) 4 (+/-15.4) 3.8 (+/-14.0)
 (n/%) (n/%) (n/%) 
Diagnosis of FAP  1 (11.1) 0 (0) 1 (25) 
Diagnosis of UC  8 (88.9) 5 (100) 3 (75) 
Gender    
      Male 6 (66.7) 3 (60) 3 (75) 
      Female  3 (33.3) 2 (40) 1 (25) 
 
4.3 Compliance 
 The mean percentage of days of compliance on the 5 g dose is 95.6% for the 
inulin group vs. 100% for the placebo group (Table 4.2). The mean percentage of days 
compliant on the 10 g dose is 70.4% for the inulin group vs. 100% for the placebo 
group.  
 The mean percent of days in which participants required a half dose of the 
treatment, due to intolerance of the full dose, was 15.6 % for the inulin group vs. 0% for 
the placebo group. Two participants, P-01 and P-04, had very low compliance due to 
side effects at the 10 g dose and their dose was reduced to 5 g. Both participants 
subsequently asked to stop participation in the study when their symptoms continued at 
the 5 g dose.  
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Table 4.2: Comparison of Percent Compliance by Participants and Comparison by  
Allocated Supplement  
Allocated 
Supplement 
Participant 
Number 
Days compliant on 
 5 g dose (%) 
Days 
compliant on 
10 g dose (%) 
Percent of 
days 
requiring 
half dose 
Inulin  P-01 100 33 67 
        Inulin  P-03 86 88 0 
        Inulin          P-04 100 46 11 
        Inulin          P-07 92 85 0 
        Inulin          P-08 100 100 0 
Mean for Inulin Group 95.6 70.4 15.6 
        Placebo          P-02 100 100 0 
        Placebo          P-05 100 100 0 
        Placebo          P-06 100 100 0 
        Placebo          P-09               N/A           N/A         N/A 
Mean for Placebo Group               100           100             0 
 
4.4 Symptoms  
 Repeated measures ANOVA were performed to compare group means (inulin 
group versus placebo group) for the symptoms. However, due to a small sample size, a 
lower power of 0.2 was established and no statistical significance was determined for 
any of the symptoms. The comparisons of group means have been presented graphically. 
More detailed individual participant data, graphs, and analysis are presented in the 
Appendix 7: Detailed Symptom Data and Analysis. 
 
 4.4.1 Bleeding 
 Figure 4.3 shows the percent of days participants experienced the symptom of 
bleeding for the placebo group compared to the inulin group. This symptom increased in 
the inulin group upon consuming the 10 g dose, from 1.4% of days at baseline, to 0 % of 
days on the 5 g dose and 32.1% of days on the 10 g dose.   
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Figure 4.3: Bleeding- Comparison of Treatment Group Means 
 
  
 4.4.2 Fecal Urgency 
 The symptom of fecal urgency is presented in Figure 4.4.  Mean fecal urgency 
decreased in the inulin group, from 10% at baseline to 5.7% on the 10 g dose of inulin. 
Mean fecal urgency in the placebo group was 47.8% of days at baseline to 7.2% on the 
placebo.  
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Figure 4.4: Fecal Urgency- Comparison of Treatment Group Means 
 
 4.4.3 Abdominal Cramping and Pain 
 Figure 4.5 shows a comparison of group means for percent of days with the 
symptoms of abdominal cramping and pain. For the inulin group, there was a decrease 
from 19.3 % at baseline to 14.3% at 5 g, then an increase to 18.0% on the 10 g dose of 
inulin. For the placebo group, there was a decrease in symptoms, from 23.8% at baseline 
to 0% on 5 g to 1.2 % on 10 g.  
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Figure 4.5: Abdominal Pain & Cramping- Comparison of Treatment Group Means 
 
 However, when the individual data is examined (Appendix 7.3), one participant 
(P-07) in the inulin group experienced an increase in abdominal cramping and pain upon 
treatment, increasing from 50% at baseline to 76.2% at the 10 g dose. Another 
participant in the inulin group (P-04) did not experience any abdominal pain or cramping 
at baseline, but reported an increase in abdominal cramping upon treatment (14.3 % at 5 
g and 10.7 % at 10 g). This participant cited this abdominal cramping as a reason for 
dropping out of the study. 
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 4.4.4 Diarrhea 
 The symptom of diarrhea is presented in Figure 4.6. There is a slight increase in 
percent of days with diarrhea for both the placebo and inulin groups when increasing 
from baseline to the 5 g dose. 
Figure 4.6: Diarrhea- Comparison of Treatment Group Means 
 
 4.4.5 Gas  
 Figure 4.7 shows a comparison of treatment group means for the percent of days 
that participants experienced the symptom of gas. The increase in this symptom in the 
inulin group is from 0% at baseline to 15.2% on the 10 g dose.  
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Figure 4.7: Gas- Comparison of Treatment Group Means 
 
 Two participants (P-01 and P-03) in the inulin group experienced gas at the 10 g 
dose (Appendix 7.5). P-01 felt that gas was so severe that this participant had to 
discontinue taking the treatment, despite halving the dose to 5 g. This participant 
dropped out of the study due to severe gas.  
 
 4.4.6 Other Symptoms Reported 
 One participant, (P-07) of the inulin group reported pain in the rectal area. This 
pain increased from 35.7% at baseline to 78.6% at the 5 g dose and 88.1 % at the 10 g 
dose. No participants in the placebo group reported pain in the rectal area. One 
participant in the placebo group reported one day with a fever on the 10 g dose. No other 
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participants in either group reported any fevers at any period. Another participant (P-06) 
of the placebo group reported feeling tired and weak at the 5 g dose of inulin (64.3% of 
the days). No other participants reported this symptom at any time in the study.  
  
4.5 Bowel Movement Frequency 
4.5.1 Bowel Movement Frequency Baseline Data 
 Bowel movement (BM) Frequency was examined for all nine participants. The 
maximum, minimum, and mean were compared for each participant (Table 4.3) and a 
range of 4 to 18 BMs per 24 hour period was established.  
 
Table 4.3: Mean BM Frequency and Range for Each Participant at Baseline 
Group Participant Mean number of BM/day  (Range) 
Inulin P-01 10.7 (9 – 12) 
Inulin P-07 11.3 (8-16) 
Inulin P-08 5.5 (4-8) 
Inulin P-03 7.3 (6-9) 
Inulin P-04 10.4 (9-12) 
Placebo P-05 7.3 (6-9) 
Placebo P-06 8.7 (7-13) 
Placebo P-02 10.5 (6-14) 
Placebo P-09 8.1 (4-18) 
 
4.5.2 Bowel Movement Frequency Baseline Data vs. Treatment Periods 
 Figure 4.8 shows the treatment group mean comparisons of BM Frequency for 
baseline, 5 g dose and 10 g dose. A mean of 9 BM per day was observed at baseline 
compared to 8.6 BM per day at the 5 g dose of inulin and 8.9 BM per day at the 10 g 
dose. 
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Figure 4.8: BM Frequency- Comparison of Treatment Group Means 
 
4.6 Subjective Overall Health Rating 
 Figure 4.9 shows a comparison of the mean scores for between the participants at 
baseline and treatment. No trends between the inulin group and the placebo group were 
noted. Figure 4.10 shows a comparison of the group mean scores. 
 
 
 
 
 
 
56 
Figure 4.9: Subjective Overall Health- Comparison of Individual Participant Data 
Figure 4.10: Subjective Overall Health- Comparison of Treatment Group Means 
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4.7 SIBDQ Scores 
 4.7.1 Comparison of SIBDQ Scores at Baseline vs. Supplementation 
 A paired-t test was performed for each of the 10 questions in the SIBDQ, 
comparing baseline versus supplementation for the inulin group and the placebo group 
(Table 4.5). No statistical difference was found between the groups for any of the 
questions.  
Table 4.4: Comparison of SIBDQ Scores for Inulin and Placebo Groups: 
Baseline vs. 5g dose Treatment 
Question 
# 
Measure Category Test Statistic (p) 
1 Fatigue/Tiredness Systemic 0.172 
2 Delay/Cancel Social Engagement Social 0.103
3 Difficulty Sport/Leisure Social 0.673
4 Pain in Abdomen Bowel 0.253
5 Depressed/Discouraged Emotional 0.172
6 Large Amounts of Gas Bowel 0.604
7 Problems Maintaining Weight Systemic 0.436
8 Feeling Relaxed Emotional 0.534
9 Feeling of Need to Use Toilet Bowel 0.604
10 Feeling of Anger Emotional 0.321
 
 P-04 and P-09 did not provide SIBDQs during the 5 g supplementation period, 
and were therefore excluded from this analysis. The SIBDQ total score was significantly 
improved at supplementation compared to baseline for P-01 (p= 0.002) and P-03 (p= 
0.034). 
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Table 4.5 SIBDQ Scores Compared at Baseline and 5 
g Dose Treatment for Each Participant 
Allocated  
Supplement 
Participant  Difference 
in  
Total Score 
p* 
Inulin P-01 17 0.002* 
Inulin P-03 14 0.034* 
Inulin P-07 3 0.434 
Inulin P-08 0 1 
Inulin P-04 N/A N/A 
Placebo P-02 -5 0.138 
Placebo P-05 0 1 
Placebo P-06 2 0.343 
Placebo P-09 N/A N/A 
 
 
4.8 Incidents of Pouchitis 
 Two participants self-described incidents of pouchitis in their study diaries and 
reported that they were prescribed Metronidazole by their physicians for the treatment of 
this condition. Participant P-02 (placebo) was diagnosed with pouchitis once in the 
baseline period and three times on the 10 g dose treatment period. Participant P-03 
(inulin) was diagnosed once with pouchitis during the 10 g dose treatment period, but 
not during the baseline or 5 g dose period. 
 
4.9 Medications and Supplements 
 Appendix 4 describes the medications and supplements that participants took at 
baseline and throughout the treatment periods.  
 Participant P-01 (inulin) took a low dose of Metamucil (containing 3.4 g of 
psyllium/day) during baseline and treatment periods. Participant P-02 (placebo) and 
participants P-03, P-07, and P-08 of the inulin group all required Metronidazole at 
baseline and/or during treatment for incidents of pouchitis. Metronidazole is an 
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antibacterial agent against anaerobic bacteria (Canadian Pharmacists Association, 2005). 
Participant P-03 (inulin) took many herbal supplements and probiotic supplements: 
“Jade Windscreen” herbal formula for respiratory health, Acidophilus and Bifidus, 
UNDA # 3, 37, 50 (Herbal Supplements), and Replete Probiotic Formula (130 billion 
CFU of L. acidophilus, B. bifidum, B. lactis, and L. salivarius) and also took Lomotil 
and Imodium. Participant P-04 of the inulin group consumed once weekly medications 
for Rheumatoid Arthritis, including Methotextrate. 
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CHAPTER 5 
DISCUSSION 
 
5.1 A Discussion of the Results 
This discussion provides a detailed response to the findings of the study in 
relation to the literature. The efficacy and safety of inulin supplementation in IPAA 
patients with chronic pouchitis and the impact on the quality of life is examined. Also, 
future directions for research are proposed. 
 
5.1.1 Practicality and Safety of Inulin Supplementation 
 The first objective was to determine if inulin supplementation is a practical and 
safe nutritional recommendation for patients with chronic pouchitis. Based on the 
adverse effects reported, the subsequent drop-outs, and the low compliance observed in 
this study in participants taking the inulin versus those on placebo, at this point the 
author would not advise that inulin is a practical nutritional recommendation. These 
results are in sharp contrast to Welters et al., (2002); in which 20 participants received 
24g/d of inulin, but no side effects were reported. They did report that one patient 
dropped out of the study due to lactose intolerance and that there were no other adverse 
effects. The authors did not describe how the lactose intolerance was diagnosed and 
differentiated from other causes of similar symptom patterns, so it may be possible that 
the symptoms of lactose intolerance as they report could actually be due to side effects 
of the inulin supplementation. 
 The participants of our study received a maximum dose of only 10 g/day, yet 2 
of 5 participants on inulin experienced side effects severe enough that they were 
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required to discontinue supplementation and stop participation in the study. Thus it is 
surprising to see that Welters et al. (2002) did not report any side effects when they used 
more than twice the dose of inulin supplementation provided in our study. The 
recommended average nutrient intake level for fibre, the Adequate Intake (AI) for adults 
aged 19-50 is 25 g/day for females; 38 g/day for males (Health Canada, 2006). Thus the 
24 g/d of supplemented fibre nearly fulfills the AI for fibre for women before any usual 
dietary fibre is even considered.  
 Gastrointestinal distress such as cramping, bloating, flatulence, and diarrhea has 
been observed in healthy individuals at intakes of inulin ranging from 14 to 18 g/d 
(Davidson & Maki, 1999; Pedersen, Sandstrom, & Amelsvoort, 1997). An ileal pouch is 
smaller than a colon and therefore, it would be expected that participants would have 
less capacity for flatulence and would experience pain sooner from smaller amounts of 
inulin. Since the participants in our study were already experiencing gastrointestinal 
discomfort due to problems with their IPAA, we tried to protect our participants from 
potential side effects of the additional fibre of the inulin supplementation by starting 
them on 5 g and then increasing the dose to 10 g after 2 weeks. Welters et al. (2002) did 
not slowly introduce the inulin and therefore we would expect to see gastrointestinal 
symptoms with the sudden ingestion of 24 g/d of supplemented fibre.  
 The adverse effect of cramping and gas experienced by one of the participants 
can be reasonably linked to the fermentation of inulin which could be expected to occur 
within the pouch. However, with regards to the adverse effect of bleeding experienced 
by one of the participants in this study, it is difficult to determine if inulin was 
specifically responsible for the symptoms since the researchers did not conduct physical, 
histological, or endoscopic examinations. It is possible that the rectal bleeding occurred 
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from peri-anal irritation due to wiping after frequent bowel movements, which may or 
may not have been exacerbated by inulin supplementation. The participant who 
experienced rectal bleeding also took once weekly medications for Rheumatoid 
Arthritis, including Methotextrate, a medication that could cause diarrhea and 
gastrointestinal ulceration/bleeding (Canadian Pharmacists Association, 2005). There is 
a possibility that the bleeding experienced by this patient could potentially be linked to 
the use of Methotextrate; however, the participant had been on these medications for a 
long period of time before the start of this study and had not previously experienced 
bleeding.  
 The allowance for participants to take other medications and supplements in this 
trial may also partially explain the adverse symptoms experienced by the other 
participant who dropped-out. Participant P-01 of the inulin group took a low dose of 
Metamucil (containing 3.4 g of psyllium/day) for years before the trial and continued 
during baseline and the treatment periods. The gastrointestinal effects of Metamucil 
include bloating, abdominal pain, flatulence, and diarrhea (Canadian Pharmacists 
Association, 2005). Nevertheless, the symptoms that this participant experienced could 
not be blamed solely on the Metamucil, as the participant had tolerated it for many years 
before taking the inulin. Psyllium, the main component of Metamucil, is resistant to 
fermentation by typical microflora and therefore it may have only contributed minimally 
to gas production (Marlett & Fisher, 2003). 
 In comparing the adverse effects that we report in our findings to those effects 
observed in the probiotic literature, there are some interesting similarities. Although 
most probiotic trials did not observe any adverse effects (Elahi et al., 2007), Mimura et 
al. (2004) reported that 1/20 of participants receiving VSL #3 dropped out of their study 
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due to abdominal cramps, vomiting, and diarrhea. Shen et al. (2005) reported that at the 
8 month follow-up, (2/31; 6.5%) of patients had discontinued taking VSL #3 due to 
intolerable adverse effects; one patient developed bloody bowel movements immediately 
after starting the treatment, and one patient developed severe constipation, bloating, and 
gas. Neither Shen et al. nor Mimura et al. discuss these adverse effects, but it is 
interesting that bloody bowel movements occurred in both our prebiotic trial and two 
probiotic trials. Future research may wish to examine the heme content of stools during 
prebiotic and probiotic trials of IPAA patients. 
 
5.1.2 The Effect of Inulin on Pouchitis and Problems of Fecal Frequency 
 The second objective was to determine if inulin supplementation affects the 
incidence of pouchitis and problems of fecal frequency in patients with IPAA. Based on 
the findings reported, we conclude that inulin appears to be ineffective in reducing the 
incidence of pouchitis and fecal frequency; although the trial did not have a large 
enough sample size to determine statistical significance. 
 In determining average fecal frequency in IPAA patients, Simchuk and Thirlby 
(2000) report an mean 24 hour frequency of 6.1 ± 0.2 for 114 patients and Shibata et al 
(2006) reported a mean 24 hour frequency of 7 (range 4-18) for 67 patients. Therefore 
the mean 24 h frequency range we found (4-18 per BM per day at baseline) is consistent 
with the averages found in the literature.  Inulin supplementation did not appear to have 
an effect on fecal frequency in this study.  
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5.1.3 The Effect of Inulin on Quality of Life of Patients  
 The third objective was to determine if inulin supplementation affects the quality 
of life in people with IPAA. Unfortunately, no changes in group mean SIBDQ scores 
observed.  However, the SIBDQ total score was significantly improved at 
supplementation compared to baseline for P-01 (p= 0.002) and P-03 (p= 0.034). This is 
an interesting observation, since P-01 dropped out of the study due to reported side 
effects. 
 Turina et al. (2006) reported significantly lower QOL in patients with chronic 
pouchitis (p< 0.01) than patients without pouchitis. However, despite suffering from 
chronic pouchitis, our participants in the inulin group started with high SIBDQ scores, 
thus a regression toward the mean might explain why we did not observe a change in 
group mean scores. In contrast to Turina et al. (2006), Stocchi and Pemberton (2001) 
followed-up on patients post-IPAA and reported that although pouchitis occurred in 
more than half of the patients reviewed, the mean patient satisfaction with the procedure 
was high, 8.4 (on a scale of 0 being dissatisfied and 10 being extremely satisfied). 
Lichtenstein et al. (2006) purport that the QOL of UC patients is so poor that most 
clinical studies have shown an increase in quality of life in patients after the IPAA 
procedure. Thus the high baseline SIBDQ scores observed in the inulin group could 
potentially be explained by previously poor QOL prior to the IPAA procedures.  
 
5.2 A Comparison to the Current Literature  
 There are several differences between our study and the Welters et al. (2002) 
study. As previously mentioned, Welters et al. provided 24 g/d of inulin, versus the 
doses of 5 and 10 g/d of inulin our participants ingested in this study. No other 
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medications or supplements were reported as being taken by participants in the Welters 
et al. study. Welters et al. used the PDAI to diagnose pouchitis, whereas our study relied 
on a symptom diary to evaluate the presence of pouchitis.  
 Another difference between our study and the Welters et al. (2002) is the method 
of inulin delivery. The participants of our study were instructed to add inulin to a hot 
beverage in the morning and evening. Welters et al. study participants consumed inulin 
via a component of a commercially-available milk-based (and therefore lactose-
containing) beverage that they drank twice daily. Interestingly, Kuisma et al. (2003) 
found an association between dietary lactose, fecal bacteria, and pouch morphology, and 
suggested that lactose may have prebiotic properties. They reported that lactose was 
inversely correlated with total aerobes (r = -0.45; p= 0.019). Thus, it is the possible that 
our results varied so greatly from the Welters et al. study because the inulin in our study 
was not paired with lactose.  More research is required to determine if lactose, alone and 
in conjunction with inulin, has prebiotic properties in IPAA patients.  
 However, in contrast to the conclusions of the Welters et al. article (2002), in the 
Meijer et al. (2000) article (a different set of data published from the Welters et al. 
article), the authors concluded that inulin did not influence inflammation or have an 
effect on pouch mucosal functioning because neither epithelial gene expression nor 
epithelial homeostasis was significantly changed by inulin supplementation. Mucosal 
morphology, epithelial cell proliferation and cell death were not altered by inulin 
supplementation. The Meijer et al. results are more consistent with the lack of significant 
effects in our study.  
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5.3 Limitations 
 This trial was limited to subjective reporting of clinical signs in study diaries 
completed by participants. Participants’ symptoms were not corroborated by histological 
or endoscopic examinations. Since the ultimate goal of this research is to improve 
quality of life of patients who suffer from chronic pouchitis, the researchers did not feel 
it was appropriate to perform invasive procedures such as pouchograms or biopsies to 
determine if inflammation of the pouch was present.  
 The population of patients suffering from pouchitis in Saskatoon is small (n= 
93), which subsequently limited the sampling.  
 The dietary behaviors and lifestyle habits of the participants were not evaluated 
in this clinical trial, thus it is possible that these factors may have influenced 
gastrointestinal symptoms, such as fecal frequency. However, it was felt that a lengthy 
baseline and supplement period would provide sufficient data to account for minor 
dietary and lifestyle fluctuations. Any supplements and medications that a participant 
was taking at baseline were permitted and reported during the treatment period. Other 
supplements and medications could confound the findings and therefore, make it 
difficult to isolate the effects of inulin that could be attributed to this study. However, 
the first objective of this study was to determine if inulin supplementation is a practical 
and safe nutritional recommendation for patients with chronic pouchitis; it could be 
harmful and impractical if participants were required to stop taking their preventative 
medications and treatments for acute onsets of pouchitis. Therefore, participants were 
permitted to use supplements and medications throughout the study. 
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5.4 Future Research 
 This pilot study has pointed to the potential problems associated with inulin 
supplementation; however, our findings appear to conflict with the other reported 
studies. Specifically, larger randomized trials are needed. Future research should involve 
determining a dose and method of delivery of inulin that is acceptable and that produces 
significant bifidogenic effects in specifically in patients with IPAA. Further exploration 
of synbiotic therapy for pouchitis may be warranted, based on the many positive results 
of the probiotic trials in UC and IPAA. The Friedman and George (2002) study of 
Lactobacillus GG and FOS in IPAA patients was successful; however larger, 
randomized trials have not yet been conducted.  
 Allowance for other supplements and medications and not evaluating dietary and 
lifestyle habits made it difficult to isolate the effects of inulin in our study, therefore 
future studies would need to strictly regulate and control for confounding factors. Any 
future studies of prebiotics or synbiotics for inulin should use the Pouchitis Disease 
Activity Index (PDAI) to evaluate efficacy, as this index is very sensitive and specific in 
diagnosing pouchitis and was used by Welter et al. (2002). It is interesting that bloody 
bowel movements occurred in both our prebiotic trial and two probiotic trials. Future 
research may wish to examine the heme content of stools during prebiotic and probiotic 
trials of IPAA patients. 
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APPENDIX 2 
 
PARTICIPANT INFORMATION AND CONSENT FORM 
 
Study Title: The Effect of Inulin Supplementation on Relapse Rates and Quality of Life in Patients 
with Pouchitis. 
 
Principal Investigator for this study:  
 
Wendy Dahl RD PhD Adjunct Professor 
College of Pharmacy and Nutrition, University of Saskatchewan. 
Ph: 655 1310 Fax: 966 6377   
Email: wendy.dahl@saskatoonhealthregion.ca 
  
Sub-investigators:  
 
Dr. S. C. Kanthan FRCSC, FRCS, Associate Professor, General and Colorectal Surgery, Royal 
University Hospital 
Lindsay Hauser, Graduate Student, College of Pharmacy and Nutrition, University of 
Saskatchewan 
Natasha Haskey, Pediatric Dietitian, Royal University Hospital 
Nadia Rodych, Nutritional Support Services Dietitian, Royal University Hospital  
 
Study Sponsor: Royal University Hospital Foundation 
 
Introduction: You are invited to participate in this research study because you have a 
surgically-created pouch, following the removal of your large intestine. Participation in this study 
may help to determine if inulin, a fibre ingredient, improves pouch health and reduces infections 
of the pouch (known as pouchitis). Inulin is known as a prebiotic, a food ingredient that increases 
the number of good bacteria in the gut. 
 
Voluntary Participation: Participation in this study is voluntary and you have the right to refuse 
participation or withdraw from the study at anytime. If you do not wish to participate, you do not 
have to provide any reason for your decision, nor will you lose the benefit of any care to which 
you are entitled or are presently receiving. 
 
Purpose of the Study: The purpose of this study is to determine if consuming inulin, a fibre 
ingredient, will decrease pouch infections and improve quality of life in patients with pouches. 
 
Benefits: There may not be direct benefits to you for participating in this study. Knowledge 
gained from this study may help to improve care for people living with a pouch. 
 
Description of the Research:  This study may help us to determine if consuming inulin will reduce 
pouch infections and improve quality of life for people with pouches. Consuming inulin may increase the 
numbers of good bacteria in the pouch and result in improved pouch health. We will be enrolling up to 60 
people with pouches into this study. Participants will be placed into one of two groups at random 
(determined with a randomization table) -- each participant will take a supplement for six months. 
 
The treatment group will receive the inulin supplement and the control group will receive a maltodextrin 
(sugar) supplement. It is expected that those participants consuming the inulin will have improved pouch 
health while those consuming the maltodextrin will have no change in pouch health. Neither the 
researchers nor the participants will know what group the participants are placed into until the end of the 
study. 
 
Participants will be asked to record when they take the supplement and any pouch problems that they 
may have in a study diary that will be provided. Participants will be interviewed about their pouch health 
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and their quality of life by a graduate student four times, once at the beginning of the study and every 
second month for 6 months. 
 
 
Procedures: If you choose to participate in this study: 
 
1. You will be randomly placed into either the control group or the treatment group and receive a 
supplement. You will not know which group you were placed or which supplement you were 
given until the end of the study. 
 
2. You will be given a two-month supply of either inulin (a fibre) or maltodextrin (a sugar), 
provided in daily 10 gram plastic packages. 
 
3. You will be asked to consume the contents of one package of inulin or maltodextrin each day 
for 6 months. At the beginning of the study, the graduate student will teach you how to mix the 
inulin or maltodextrin into your usual beverages and food. 
 
4. You will be given a study diary to record your intake of the inulin or maltodextrin and to record 
pouch symptoms. 
 
5. You will be interviewed by the graduate student four times, once at the beginning of the study 
and every second month for 6 months. You will be asked questions about symptoms and quality 
of life (see Short Inflammatory Bowel Disease Questionnaire attached). 
 
6. If you do develop any symptoms of pouchitis such as abdominal pain, diarrhea, urgency, 
rectal bleeding or fever, please contact Dr. Kanthan’s office – 966-8174. Dr. Kanthan (or other 
physician) will provide you with the standard medical treatment for pouchitis such as antibiotics. 
With your consent, he may carry out endoscopic (visual observation of the pouch using a scope) 
and/or histologic (lab) tests. The results of these tests will be made available to you and the 
researchers. If emergency medical problems arise that require Dr. Kanthan (or other physician) 
to know which supplement you are taking, he or she will be informed. If you are unable to reach 
Dr. Kanthan, please contact your family physician or go directly to emergency depending on the 
degree of your symptoms. 
 
7. Your medical chart (at Royal University Hospital only) will be reviewed at the end of the study 
to assess any relevant medical information, symptoms or treatments not accounted for in your 
self-report study diaries. 
 
Confidentiality: While absolute confidentiality cannot be guaranteed, every effort will be made 
to ensure that the information you provide for this study is kept entirely confidential. Your name 
will not be attached to any information, nor mentioned in any study report, nor be made available 
to anyone except the research team. It is possible that the research team may wish to present 
results from this study in scientific journals or at related conferences and workshops, but your 
identity will not be revealed. 
 
Voluntary Participation: Your participation in this study is entirely voluntary. You have the right to 
refuse participation and to withdraw from the study at any time, for any reason. Early withdrawal from the 
study will not result in any sort of penalty. 
 
Potential Risks: There are no known risks associated with study. Some individuals may experience 
increased gas production and increased stool frequency. As with any intervention, there may be 
unforeseen risks. 
 
Research Related Injury: There will be no costs to you for your participation in this study. You 
will not be charged for any research procedures. In the event that you become ill or injured as a 
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result of participating in this study, necessary medical treatment will be made available at no 
cost to you. By signing this document, you do not waive any of your legal rights.  
 
Compensation: There will be no compensation for participation in this study. 
 
 
 
 
 
Contacts: If you have any questions, please contact: 
 
Wendy Dahl RD PhD Adjunct Professor 
College of Pharmacy and Nutrition, University of Saskatchewan. 
Ph: 655 1310  Fax: 966 6377   
Email: wendy.dahl@saskatoonhealthregion.ca 
 
In addition, you may contact the following sub-investigators:  
 
Dr. S.C. Kanthan, Surgeon, Royal University Hospital. Ph: 966-8174   
 
Natasha Haskey, Dietitian, Royal University Hospital. Ph: 655-6512  
 
Lindsay Hauser, Graduate Student, College of Pharmacy and Nutrition, University of 
Saskatchewan.  
Ph: 978-4250 or 221-7853. Email: lindsay.hauser@usask.ca 
 
This study has been approved, on ethical grounds, by the Biomedical Research Ethics Board 
(Bio-REB) of the University of Saskatchewan. If you have any questions about your rights as a 
research subject, you may contact the chair of the Biomedical Ethics Board, c/o the Office of 
Research Services, University of Saskatchewan at (306) 966-4053. 
 
The contents of this consent form have been explained to me. I have been able to ask questions 
about the study and these questions have been answered to my satisfaction. I have received a 
copy of the consent form for my own records. I freely consent to participate in this study. By 
signing this document, I am not waiving any of my legal rights by signing this consent form. 
 
SIGNATURES 
 
Study Volunteer: _________________________Date: __________________ 
 
    
Please clearly print your name here: ______________________________  
  
 
 
 
Research Coordinator: ____________________ Date: __________________ 
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APPENDIX 3: 
LETTER OF INVITATION 
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APPENDIX 4: 
SYMPTOM DIARY POUCHITIS STUDY 
 
 
Month 
_____ 
(date) 
Did you 
take the 
powder? 
 
How would 
you rate your 
overall 
health today?
How many 
bowel 
movements 
did you have 
today? 
Please check the boxes if you 
experienced these symptoms 
today. You may write any 
additional comments on the 
back of this page. 
Monday 
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
Tuesday  
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
Wednesday 
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
Thursday 
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
Friday 
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
Saturday 
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
Sunday 
_____ 
(date) 
? Yes 
? No 
? Excellent    
? Very Good  
? Good    
? Fair  
? Poor 
 ? Blood in feces 
? Urgency of bowel movements 
? Abdominal cramps 
? Fever (oral temp > 37.5 º C) 
? Other___________________ 
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APPENDIX 5:  
THE SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE 
This questionnaire is designed to find out how you have been feeling during the last 2 
weeks. You will be asked about symptoms you are having as a result of your 
inflammatory bowel disease, the way you have been feeling in general, and how your 
mood has been.  
1. Please indicate how often the feeling of fatigue or tiredness has been a problem 
for you during the last 2 weeks by picking one option from the following: 
?All of the time 
?Most of the time 
?A good bit of the time 
?Some of the time 
?A little of the time 
?Hardly any of the time 
?None of the time 
 
2. How often during the last 2 weeks have you had to delay or cancel a social 
engagement because of your bowel problem?  
?All of the time 
?Most of the time 
?A good bit of the time 
?Some of the time 
?A little of the time 
?Hardly any of the time 
?None of the time 
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3. How much difficulty have you had, as a result of your bowel problems, doing 
leisure or sports activities you would have liked to have done over the last 2 weeks?  
?A great deal of difficulty, activities made impossible 
?A lot of difficulty 
?A fair bit of difficulty 
?Some difficulty 
?A little difficulty 
?Hardly any difficulty 
?No difficulty; the bowel problems did not limit sports or leisure activities 
 
4. How often during the last 2 weeks have you been troubled by pain in the 
abdomen?  
?All of the time 
?Most of the time 
?A good bit of the time 
?Some of the time  
?A little of the time 
?Hardly any of the time 
?None of the time 
92 
5. How often during the last 2 weeks have you felt depressed or discouraged?  
?All of the time 
?Most of the time 
?A good bit of the time 
?Some of the time 
?A little of the time 
?Hardly any of the time 
?None of the time 
 
6. Overall, in the last 2 weeks, how much of a problem have you had passing large 
amounts of gas?  
?A major problem 
?A big problem 
?A significant problem 
?Some trouble 
?A little trouble 
?Hardly any trouble 
?No trouble 
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7. Overall, in the last 2 weeks, how much of a problem have you had maintaining or 
getting to the weight you would like to be?  
?A major problem 
?A big problem 
?A significant problem 
?Some trouble 
?A little trouble 
?Hardly any trouble 
?No trouble 
 
8. How often during the last 2 weeks have you felt relaxed and free of tension? 
?None of the time 
?A little of the time 
?Some of the time 
?A good bit of the time 
?Most of the time 
?Almost all of the time 
?All of the time 
94 
9. How much of the time during the last 2 weeks have you been troubled by a 
feeling of having to go to the toilet even though your bowels were empty?  
?All of the time 
?Most of the time 
?A good bit of the time 
?Some of the time 
?A little of the time 
?Hardly any of the time 
?None of the time 
 
10. How much of the time during the last 2 weeks have you felt angry as a result of 
your bowel problem?  
?All of the time 
?Most of the time 
?A good bit of the time 
?Some of the time 
?A little of the time 
?Hardly any of the time 
?None of the time 
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Legend: 
  = Placebo Treatment Period  
  = Inulin Treatment Period 
DO-1= Participant dropped-out of study 
because he was experiencing very 
uncomfortable gas.  
DO2= Participant dropped out of study 
because she was experiencing bleeding 
and cramping 
DO-3= Participant dropped-out of study 
because he was diagnosed with Crohn’s 
disease 
C= Early cessation of the study 
Participant P-02 P-05 P-06 P-09 P-01 P-03 P-04 P-07 P-08 
Assigned 
Treatment 
Placebo Placebo Placebo Placebo Inulin Inulin Inulin Inulin  Inulin 
Baseline 
4 weeks 
No 
Treatment 
         
Low Dose 5 g 
2 weeks 
 
   DO-3      
High Dose 
10g 
6 weeks 
 
 
 
 
     
 
 
 
 
 
DO-1 
 
 
 
 
 
 
 
 
 
 
 
 
DO-2 
 
 
 
 
 
 
C 
 
 
 
 
 
 
C 
High Dose  
10 g 
8 weeks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
C 
 
C 
   
 
 
 
C 
   
High Dose  
10 g  
8 weeks 
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CLINICAL COURSE FOR EACH PARTICIPANT 
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APPENDIX 7: 
DETAILED INDIVIDUAL SYMPTOM DATA AND ANALYSIS 
Appendix 7.1 Bleeding 
 As depicted in Figure 7.1, the symptom of blood in feces and blood upon wiping 
occurred in 3 of 9 participants. One participant in the placebo group (P-05) had this 
symptom at baseline, and the bleeding increased at 5 g dose and decreased at 10 g dose. 
Two participants in the inulin group (P-07 and P-04) experienced this symptom as well. 
P-04 did not experience bleeding at baseline or at the 5 g dose, but experienced bleeding 
at the 10 g dose and subsequently dropped out of the study. P-07 had bleeding at 
baseline, decreased bleeding at 5 g dose, and increased bleeding at 10 g dose.   
Figure 7.1: Bleeding
Note: Each vertical grid represents one participant. 
No bars present in the grid indicates zero percent of days with 
symptoms for that participant or time period.
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Appendix 7.2 Fecal Urgency 
 The symptom of fecal urgency is examined in Figure 7.2. Participant P-05 of the 
placebo group experienced fecal urgency 82.6% of days at baseline, dropping 
dramatically to 7.1 % at the 5 g dose of the placebo. Participant P-02 of the placebo 
group experienced fecal urgency 28.6 % of days at baseline, increased dramatically at 
the 5g dose to 85.7 %, then dropped to 16.7 % at the 10 g dose.  
 Two participants in the inulin group experienced fecal urgency at baseline, and 
experienced no symptoms at the 5 g dose. However, upon increasing to the 10 g dose, 
the symptom of urgency returned. 
Figure 7.2: Fecal Urgency
Note: Each vertical grid represents one participant. 
No bars present in the grid indicates zero percent of days with 
symptoms for that participant or time period.
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Appendix 7.3 Abdominal Cramping & Pain 
 Figure 7.3 shows how one participant (P-07) in the inulin group experienced an 
increase in abdominal cramping and pain upon supplementation, increasing from 50% at 
baseline to 76.2% at the 10 g dose. Another participant in the inulin group (P-04) did not 
experience any abdominal pain or cramping at baseline, but reported an increase in 
abdominal cramping upon supplementation (14.3 % at 5 g and 10.7 % at 10 g). This 
participant cited this abdominal cramping as a reason for dropping out of the study.  
Participants in the placebo group who experienced abdominal pain or cramping at 
baseline reported a decrease in abdominal pain upon supplementation (60.7 % for P-06, 
7.1 % for P-05).  
 
Figure 7.3: Abdominal Cramping and Pain
Note: Each vertical grid represents one participant. 
No bars present in the grid indicates zero percent of days with 
symptoms for that participant or time period.
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Appendix 7.4 Diarrhea 
 Two participants, one from the inulin group (P-08) and one from the placebo 
group (P-05) experienced increased diarrhea at the 5 g dose. One participant in the inulin 
group (P-01) who did not report diarrhea at baseline or the 5 g dose experienced diarrhea 
at the 10 g dose. One participant in the inulin group showed no change at the 5 g dose, 
but showed a decrease in diarrhea on the 10 g dose.  
Figure 7.4: Diarrhea
Note: Each vertical grid represents one participant. 
No bars present in the grid indicates zero percent of days with 
symptoms for that participant or time period.
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Appendix 7.5 Gas  
 Two participants (P-01 and P-03) in the inulin group experienced gas at the 10 g 
dose Figure 7.5. P-01 felt his gas was so severe that he had to discontinue taking the 
supplement, despite halving his dose to 5 g. This participant dropped out of the study 
due to this severe gas he experienced. One participant in the placebo group experienced 
a mild increase in gas, but the gas decreased at the 10 g dose. 
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Figure 7.5: Gas 
Note: Each vertical grid represents one participant. 
No bars present in the grid indicates zero percent of days with 
symptoms for that participant or time period.
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Appendix 7.6 BM Frequency 
 Eight participants were plotted on Figure 7.6 (P-09 was excluded because he 
only completed baseline). The figure represents mean bowel movement (BM) frequency 
at three time periods: at the baseline period, at the 5 g supplementation period and at the 
10 g supplementation period.  
 
 
 
 
 
 
 
 
Figure 7.6: BM Frequency
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APPENDIX 8:  
 
MEDICATIONS 
 
Please list any medications or supplements that you are currently taking 
(including vitamins, minerals, probiotics, etc.). 
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APPENDIX 9:  
RESEARCHER’S NOTES ON POTENTIAL EFFECTS OF MEDICATIONS 
 
1. Participant: P-01  
Treatment: Inulin 
? Participant took a low dose (3.4 g of psyllium/day) of Metamucil during baseline 
and treatment periods. 
Researcher’s note: A relevant adverse effect is bloating, abdominal pain, flatulence and 
diarrhea. However, the participant tolerated Metamucil before taking the inulin. It could 
be the combined effect, as discussed in the results section.  
 
2. Participant: P-02  
Treatment: Placebo  
? This participant took the Flagyl at baseline and 3 times while taking the placebo 
at full dose to decrease his BM frequency. 
Researcher’s note: Flagyl (Metronidazole) - is an antibacterial against anaerobic 
bacteria. A relevant adverse effect is diarrhea 
 
3. Participant: P-03 
Treatment:  Inulin 
? Lomotil (Anti-diarrheal): bloating and cramps 
? Imodium (anti-diarrheal): abdominal cramping 
? “Jade Windscreen” herbal formula for Respiratory health 
? Multivitamin 
? Vitamin C 1 tablet per day: can be abdominal cramps 
? Acidophilus and Bifidus  
? UNDA # 3, 37, 50 (Herbal Supplements) 
? Replete Probiotic Formula: 130 billion CFU of L. acidophilus, B. bifidum, B. 
lactis, and L. salivarius in each packet. 
? Flovent and Solvent for asthma:  
? * Flagyl taken 2 weeks into 10 g dose: adverse effect could be diarrhea 
Researcher’s note: Uncontrolled mix of medications and herbal formulas and probiotic 
formulations makes it difficult to determine isolated effects of Inulin  
 
4. Participant: P-04  
Treatment: Inulin 
“Every Sunday” took these medications for Rheumatoid Arthritis:  
? Methotextrate: Diarrhea and GI ulceration/bleeding 
? Gravol: shouldn’t affect GI symptoms 
? Enbrel 
Researcher’s note: ** The bleeding experienced by this patient could potentially be 
linked to her use of Methotextrate; perhaps the inulin aggravated potential ulcerations 
 
5. Participant: P-05  
Treatment: Placebo 
? Advil once during 5 g dose 
? Tylenol once during 10 g dose 
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Researcher’s note: These small doses and frequencies of medications mot likely linked 
to any interaction with inulin or side effect. 
 
6. Participant: P-06  
Treatment: Placebo 
? No medications listed.  
Researcher’s note: No interactions or side effects due to medications  
 
7. Participant: P-07 
Treatment: Inulin 
? Metronidazole (Flagyl) at baseline and 1 week into 5 g dose 
? Salofalk: (Lower GI anti-inflammatory) at baseline and 1 week into 5 g dose: 
flatulence is uncommon side effect 
 
8. Participant: P-08  
Treatment: Inulin  
? Throughout baseline and treatment, took an iron supplement 
? Apo- metronidazole (Flagyl): could cause diarrhea took for 10 days during 
baseline  
Researcher’s note: iron not likely to cause interaction or side effect since taken 
continuously 
Flagyl should be taken into consideration as a drug that may have caused a side effect 
during baseline.  
 
9. Participant: P-09  
Treatment: Placebo (but never started placebo due to Crohn’s diagnosis) 
? Nu-Cephalex: 500 mg for 1 week during baseline 
Researcher’s note: Diarrhea and cramping could be related to use of Nu-Cephalex, 
however it was only taken during baseline.  
 
